CINXE.COM
2022's Biggest Antitrust Developments and What to Expect in 2023
<!DOCTYPE HTML> <html lang="en"> <head> <meta http-equiv="Content-Type" content="text/html;charset=utf-8" /> <meta name="keywords" content="" /> <meta name="viewport" content="width=device-width, initial-scale=1" /> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="HpOBekD2dznOpkkplepER3gsT8e_5_7ZpGL_--ht5C3J4222eAWmXoFiFWS1X-8Ke41kknhviLebGjKWrhlkRQ" /> <title>2022's Biggest Antitrust Developments and What to Expect in 2023</title> <meta name="description" content="In the fifth installment of their popular annual series, John D. Carroll, Partner, Sheppard Mullin Richter &amp; Hampton LLP, and Alexis J. Gilman, Partner, Crowell and Moring LLP, are joined by Peter Herrick, Partner, Axinn Veltrop &amp; Harkrider LLP, to discuss 2022's biggest antitrust develop..." /> <!-- Facebook Open Graph --> <meta property="og:site_name" content="Buzzsprout"> <meta property="og:url" content="https://www.buzzsprout.com/221709/episodes/12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023"> <meta property="og:title" content="2022's Biggest Antitrust Developments and What to Expect in 2023 - AHLA's Speaking of Health Law"> <meta property="og:description" content="In the fifth installment of their popular annual series, John D. Carroll, Partner, Sheppard Mullin Richter &amp; Hampton LLP, and Alexis J. Gilman, Partner, Crowell and Moring LLP, are joined by Peter Herrick, Partner, Axinn Veltrop &amp; Harkride..."> <meta property="og:type" content="video.episode"> <meta property="og:image" content="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFmcHBBZnA3QmpvSlkzSnZjRG9MWTJWdWRISmxPZ3B6WVhabGNuc0dPZ3h4ZFdGc2FYUjVhVUU2RUdOdmJHOTFjbk53WVdObFNTSUpjM0puWWdZNkJrVlUiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--bfdad5b04912fa8a9db85eb3989e46c5908e2723/AHLA_Buzzsprout.jpg"> <meta property="og:image:width" content="250"> <meta property="og:image:height" content="250"> <meta property="fb:app_id" content="58375489563"> <!-- Twitter --> <meta name="twitter:card" content="player"> <meta name="twitter:site" content="@buzzsprout"> <meta name="twitter:title" content="2022's Biggest Antitrust Developments and What to Expect in 2023 - AHLA's Speaking of Health Law"> <meta name="twitter:description" content="In the fifth installment of their popular annual series, John D. Carroll, Partner, Sheppard Mullin Richter & Hampton LLP, and Alexis J. Gilman, Partner, Crowell and Moring LLP, are joined by Peter Herrick, Partner, Axinn Veltrop & Harkrider LLP, to discuss 2022's biggest antitrust developments and what attorneys should expect in 2023. Sponsored by Axinn."> <meta name="twitter:image" content="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDam9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFuZ0ZhUUo0QlhzR09nbGpjbTl3T2d0alpXNTBjbVU2RUdSbFptRjFiSFJmZFhKc1NTSTVhSFIwY0hNNkx5OTNkM2N1WW5WNmVuTndjbTkxZEM1amIyMHZhVzFoWjJWekwyRnlkSGR2Y210elgyeGhjbWRsTG1wd1p3WTZCa1ZVT2dwellYWmxjbnNHT2d4eGRXRnNhWFI1YVVFNkVHTnZiRzkxY25Od1lXTmxTU0lKYzNKbllnWTdDMVE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--2a89ede784d6e184500689d6dcbd55b204c8d4ad/AHLA_Buzzsprout.jpg"> <meta name="twitter:player" content="https://www.buzzsprout.com/221709/episodes/12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023?client_source=twitter_card&player_type=full_screen"> <!-- <meta name="twitter:player" content="https://www.buzzsprout.com/221709/episodes/12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023?client_source=twitter_card&iframe=true"> --> <meta name="twitter:player:width" content="500"> <meta name="twitter:player:height" content="210"> <meta name="twitter:player:stream" content="https://www.buzzsprout.com/221709/episodes/12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023.mp3?client_source=twitter_card"> <meta name="twitter:player:stream:content_type" content="audio/mp3"> <meta name="apple-itunes-app" content="app-id=1340502198"> <link rel="canonical" href="https://ahlapodcasts.buzzsprout.com/221709/episodes/12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023" /> <link rel="shortcut icon" href="/favicon.ico"> <link rel="shortcut icon" href="/favicon.ico"> <link type="application/rss+xml" rel="alternate" title="AHLA's Speaking of Health Law" href="https://feeds.buzzsprout.com/221709.rss"/> <link rel="apple-touch-icon" href="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFsZ0NhUUpZQW5zR09nbGpjbTl3T2d0alpXNTBjbVU2Q25OaGRtVnlld1k2REhGMVlXeHBkSGxwUVRvUVkyOXNiM1Z5YzNCaFkyVkpJZ2x6Y21kaUJqb0dSVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--1924d851274c06c8fa0acdfeffb43489fc4a7fcc/AHLA_Buzzsprout.jpg"/> <link rel="image_src" href="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFsZ0NhUUpZQW5zR09nbGpjbTl3T2d0alpXNTBjbVU2Q25OaGRtVnlld1k2REhGMVlXeHBkSGxwUVRvUVkyOXNiM1Z5YzNCaFkyVkpJZ2x6Y21kaUJqb0dSVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--1924d851274c06c8fa0acdfeffb43489fc4a7fcc/AHLA_Buzzsprout.jpg" /> <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Chivo&family=Inter:opsz,wght@14..32,100..900&display=swap" rel="stylesheet"> <script src="https://assets.buzzsprout.com/assets/public-b087c503dd139c6653c1d69056b8444508f7e57fb1059d24f6cf012291a26063.js" defer="defer" data-turbo-track="reload"></script> <script src="https://assets.buzzsprout.com/assets/website_main-8867ec67315d161cbf4b582509023d314674e151b59162f01d91aa3d429de325.js" defer="defer" data-turbo-track="reload"></script> <link rel="stylesheet" href="https://assets.buzzsprout.com/assets/tailwind-f019b0909368608906b0f44838b04ef600df547e7980f2f4f3a27c0005022a63.css" data-turbo-track="reload" /> <style> :root { --primary-color: #004e9a; --background-repeat: no-repeat; --background-size: auto; --background-url: url(''); --headline-font: Chivo, sans-serif; } h1 { font-family: var(--headline-font); line-height: 1.15 !important; letter-spacing: -0.025em; } body { font-family: "Inter", sans-serif; } .show-notes a { text-decoration: underline; } .show-notes a:hover { text-decoration: none; } .show-notes p { padding-bottom: 20px; overflow-wrap: anywhere; } .show-notes ul { padding-bottom: 20px; padding-left: 18px; list-style-type: disc; } .show-notes ol { padding-bottom: 20px; padding-left: 18px; list-style-type: decimal; } .show-notes li { padding: 3px 0; } .show-notes hr { margin: 15px 0 30px; } .transcript cite { color: #000; font-style: normal; font-weight: 600; margin-right: 8px; } .transcript time { color: #747576; } .transcript p { padding-bottom: 15px; } .trix-content a { text-decoration: underline; } .trix-content a:hover { text-decoration: none; } .trix-content { overflow-wrap: anywhere; } .website-header-background-image { height: 200px; background-image: var(--background-url); background-repeat: var(--background-repeat); background-size: var(--background-size); background-position: center; } @media (min-width: 600px) { .website-header-background-image { height: 300px; } } @media (min-width: 769px) and (min-height: 801px) { /* can't configure this with tailwindCSS and arbitrary media queries https://github.com/tailwindlabs/tailwindcss/pull/9558 */ .website-header-background-image { height: 400px; } } </style> <style> .mejs-time-current { background-image: url('https://www.buzzsprout.com/player/wave/5?color=%23004e9a') !important; } /* wave time and rail */ .mejs-time-float { display: none !important; } .custom-wave-form .mejs-audio { width: 100%; } .custom-wave-form .mejs-controls { width: 100%; height: auto; /* background-color: rgba(0, 0, 0, 0.1); */ } .custom-wave-form .mejs-time { } .custom-wave-form .mejs-time-rail { width: 100% !important; } .custom-wave-form .mejs-time-total { width: 100% !important; position: relative; } .custom-wave-form .mejs-controls .mejs-time-rail span { display: block; height: 42px; cursor: pointer; } .custom-wave-form .mejs-controls .mejs-time-handle, .custom-wave-form .mejs-controls .mejs-time-current { position: absolute; top: 0; } .custom-wave-form .mejs-time { position: absolute; font-size: 0.8rem; right: 0; bottom: -2.85rem; } .playpause-button.loading { position: relative; } .playpause-button.loading:after { content: " "; position: absolute; top: 0; bottom: 0; left: 0; right: 0; border-radius: 50%; border: 5px solid #FFF; box-sizing: border-box; border-color: #FFF transparent #FFF transparent; animation: loading-audio 1.2s linear infinite; } @keyframes loading-audio { 0% { transform: rotate(0deg); } 100% { transform: rotate(360deg); } } </style> </head> <body class="website episodes"> <header> <nav class="flex justify-between py-5 min-[900px]:py-0 px-4 md:px-7 primary-nav-bg border-0 md:border-b border-gray-100 bg-gray-50"> <div class="flex items-center gap-3 min-[900px]:gap-10"> <div class="flex min-[900px]:hidden"> <details data-controller="details-tag" data-action="click@window->details-tag#clickAway keydown.esc@window->details-tag#close:passive" class="group"> <summary> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" class="w-6 h-6 stroke-dark-green-800"> <path stroke-linecap="round" stroke-linejoin="round" d="M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5" /> </svg> </summary> <div class="absolute !top-20 z-10 left-0 right-0 bg-white shadow-lg"> <ul class="divide-y border-t [&_a]:block [&_a]:px-5 [&_a]:py-3"> <li class="block md:hidden"> <a class="md:shadow-[inset_0_6px_0px_0px_] md:shadow-[--primary-color]" href="/221709">Home</a> </li> <li> <a class="md:shadow-[inset_0_6px_0px_0px_] md:shadow-[--primary-color]" href="/221709/episodes">Episodes</a> </li> <li> <a href="/221709/about">About</a> </li> <li> </li> </ul> </div> </details> </div> <div class="min-[900px]:border-r pr-8"> <div class="flex gap-2 items-center"> <a class="w-10 h-10 block shrink-0 aspect-square" href="/221709"> <img alt="AHLA's Speaking of Health Law Artwork" class="rounded-full" src="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFmcHBBZnA3QmpvSlkzSnZjRG9MWTJWdWRISmxPZ3B6WVhabGNuc0dPZ3h4ZFdGc2FYUjVhVUU2RUdOdmJHOTFjbk53WVdObFNTSUpjM0puWWdZNkJrVlUiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--bfdad5b04912fa8a9db85eb3989e46c5908e2723/AHLA_Buzzsprout.jpg" /> </a> <a class="line-clamp-2 max-w-52 text-pretty ellipsis font-bold leading-tight" href="/221709">AHLA's Speaking of Health Law</a> </div> </div> <ul class="hidden min-[900px]:flex items-center gap-6 lg:gap-10 text-sm lg:text-base font-medium [&_a]:block [&_a]:py-7 [&_a]:whitespace-nowrap"> <li class="block md:hidden"> <a class="md:shadow-[inset_0_6px_0px_0px_] md:shadow-[--primary-color]" href="/221709">Home</a> </li> <li> <a class="md:shadow-[inset_0_6px_0px_0px_] md:shadow-[--primary-color]" href="/221709/episodes">Episodes</a> </li> <li> <a href="/221709/about">About</a> </li> </ul> </div> <div class="flex gap-5 lg:gap-8 items-center pl-0 md:pl-4 font-medium [&_a]:whitespace-nowrap"> <a href="/221709/episodes?search=true"> <svg width="23" height="24" viewBox="0 0 23 24" fill="none" xmlns="http://www.w3.org/2000/svg" class="hidden md:block w-4 fill-black"> <path d="M9.55995 19.5599C11.6693 19.5613 13.7169 18.847 15.3664 17.5335L21.0364 23.2035L22.5622 21.6777L16.8936 16.0063C18.6598 13.7746 19.3138 10.8594 18.6697 8.08631C18.027 5.31319 16.1567 2.98295 13.589 1.75535C11.0198 0.527673 8.03279 0.534729 5.47067 1.77644C2.90848 3.01815 1.05095 5.35815 0.42347 8.13404C-0.205126 10.9114 0.464251 13.8224 2.24176 16.0458C4.02066 18.269 6.71379 19.5627 9.55995 19.5599ZM9.55995 2.99994C11.4696 2.99994 13.3007 3.75792 14.6507 5.10932C16.0021 6.45932 16.7601 8.29025 16.7601 10.2001C16.7601 12.1099 16.0021 13.9408 14.6507 15.2908C13.3007 16.6422 11.4698 17.4002 9.55995 17.4002C7.65011 17.4002 5.81919 16.6422 4.46919 15.2908C3.11778 13.9408 2.3598 12.1099 2.3598 10.2001C2.3598 8.29025 3.11778 6.45932 4.46919 5.10932C5.81919 3.75792 7.65011 2.99994 9.55995 2.99994Z" fill=""/> </svg> </a> <a class="py-2 px-4 text-white text-sm lg:text-base font-bold bg-[--primary-color] rounded-md whitespace-nowrap" href="/221709/follow">+ Follow</a> </div> </nav> </header> <main class="max-w-screen-2xl grid grid-cols-1 md:grid-cols-[225px_minmax(100px,_1fr)] xl:grid-cols-[300px_minmax(100px,_1fr)260px] gap-0 md:gap-10 xl:gap-20 py-8 md:py-12 xl:py-20 mx-auto px-8 lg:px-16"> <div class="hidden md:block"> <div class="bg-gray-50 md:bg-inherit border-b md:border-none border-gray-100"> <img alt="2022's Biggest Antitrust Developments and What to Expect in 2023 Artwork" class="w-[200px] md:w-[300px] h-auto mx-auto rounded-lg drop-shadow-md" src="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFsZ0NhUUpZQW5zR09nbGpjbTl3T2d0alpXNTBjbVU2Q25OaGRtVnlld1k2REhGMVlXeHBkSGxwUVRvUVkyOXNiM1Z5YzNCaFkyVkpJZ2x6Y21kaUJqb0dSVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--1924d851274c06c8fa0acdfeffb43489fc4a7fcc/AHLA_Buzzsprout.jpg" /> <h1 dir="auto" class="block md:hidden pt-4 px-5 text-4xl text-center">AHLA's Speaking of Health Law</h1> <div dir="auto" class="pt-2 md:pt-6 pb-6 px-5 md:px-0 text-center md:text-start"> <input type="checkbox" name="show_more" id="show_more" value="1" class="peer hidden" /> <div class="text-sm md:text-base peer-checked:line-clamp-none line-clamp-4"> The American Health Law Association (AHLA) is the largest nonprofit, nonpartisan educational organization devoted to legal issues in the health care field with nearly 14,000 members. As part of its educational mission, AHLA's Speaking of Health Law podcasts offer thoughtful analysis and insightful commentary on the legal and policy issues affecting the health care system. AHLA is committed to ensuring equitable access to our educational content. We are continually improving the user experience for everyone and applying the relevant accessibility standards. If you experience accessibility issues, please contact accessibility@americanhealthlaw.org. </div> <label class="peer-checked:hidden font-bold cursor-pointer" for="show_more">Show More</label> </div> </div> <div> <a class="text-black underline hover:no-underline" href="/221709/episodes">All Episodes</a> </div> </div> <div> <h2 dir="auto" class="text-[--primary-color] font-semibold">AHLA's Speaking of Health Law</h2> <h1 dir="auto" class="py-3 text-2xl sm:text-4xl font-semibold">2022's Biggest Antitrust Developments and What to Expect in 2023</h1> <div class="flex items-center justify-between gap-4"> <div class="flex flex-wrap gap-2 md:gap-3.5 text-xs md:text-[13px] text-gray"> <time datetime="January 31, 2023" class="whitespace-nowrap">January 31, 2023</time> <span>•</span> <span class="whitespace-nowrap">AHLA Podcasts</span> </div> <div data-controller="timestamp" data-timestamp-copy-class="[&>div]:ring-green-500 [&>div]:bg-green-50" data-timestamp-base-url="https://www.buzzsprout.com/221709/episodes/12104405"> <button class="flex items-center gap-1 py-1.5 px-3 text-sm border rounded-full hover:bg-gray-100 transition" data-action="timestamp#setStartTimeFromAudio timestamp#update events#dispatch" data-controller=" events" data-events-name-value="dialog:open" id="share_dialog_button" type="button"> <span><svg aria-hidden="true" xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" class="w-5 h-5 fill-gray"> <path d="M5.027 10.9a8.729 8.729 0 0 1 6.422-3.62v-1.2A2.061 2.061 0 0 1 12.61 4.2a1.986 1.986 0 0 1 2.104.23l5.491 4.308a2.11 2.11 0 0 1 .588 2.566 2.109 2.109 0 0 1-.588.734l-5.489 4.308a1.983 1.983 0 0 1-2.104.228 2.065 2.065 0 0 1-1.16-1.876v-.942c-5.33 1.284-6.212 5.251-6.25 5.441a1 1 0 0 1-.923.806h-.06a1.003 1.003 0 0 1-.955-.7A10.221 10.221 0 0 1 5.027 10.9Z"/> </svg> </span> <span>Share</span> </button> <dialog id="share" size="w-11/12 md:w-8/12 lg:w-1/2" class="fixed inset-0 outline-none bg-transparent backdrop:bg-gray-800 backdrop:bg-opacity-50 border-none " data-controller="dialog" data-action="click->dialog#clickAway dialog:open@document->dialog#handleOpenEvent dialog:close@document->dialog#handleCloseEvent turbo:before-cache@document->dialog#close"> <div data-action="click->dialog#clickAway" class="fixed inset-0 overflow-x-hidden overflow-y-auto md:pt-20 pt-10 animate-position-top animate-opacity-in animate-on-show delay-150 fill-mode-forwards"> <div class="relative bg-white rounded-lg my-0 mx-5 md:mx-auto p-5 md:p-10 outline-none z-1050 w-11/12 md:w-8/12 lg:w-1/2"> <form method="dialog"> <button class="!w-min absolute right-2 md:right-4 top-3 md:top-6 outline-none hover:!bg-transparent" data-action="dialog#close" aria-label="Close Modal"> <svg aria-hidden="true" xmlns="http://www.w3.org/2000/svg" width="24" height="24" fill="none" stroke="currentColor" viewBox="0 0 24 24" class="w-8 h-8 stroke-slate-400 hover:stroke-slate-600 transition"> <path stroke-linecap="round" stroke-linejoin="round" stroke-width="3" d="M6 18 17.94 6M18 18 6.06 6"/> </svg> </button> </form> <div id="modal-content" class="py-4 px-4 md:px-8"> <h2 class="text-4xl font-semibold text-center">Share episode</h2> <div class="flex flex-wrap justify-center gap-5 mt-6"> <a title="Share on Facebook" class="flex items-center gap-2 p-4 border rounded-full hover:bg-gray-100 transition" target="_blank" href="http://www.facebook.com/sharer.php?u=https://www.buzzsprout.com/221709/episodes/12104405"> <svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 310 310" xml:space="preserve" class="w-4 h-4"> <g id="XMLID_834_"> <path id="XMLID_835_" d="M81.703,165.106h33.981V305c0,2.762,2.238,5,5,5h57.616c2.762,0,5-2.238,5-5V165.765h39.064 c2.54,0,4.677-1.906,4.967-4.429l5.933-51.502c0.163-1.417-0.286-2.836-1.234-3.899c-0.949-1.064-2.307-1.673-3.732-1.673h-44.996 V71.978c0-9.732,5.24-14.667,15.576-14.667c1.473,0,29.42,0,29.42,0c2.762,0,5-2.239,5-5V5.037c0-2.762-2.238-5-5-5h-40.545 C187.467,0.023,186.832,0,185.896,0c-7.035,0-31.488,1.381-50.804,19.151c-21.402,19.692-18.427,43.27-17.716,47.358v37.752H81.703 c-2.762,0-5,2.238-5,5v50.844C76.703,162.867,78.941,165.106,81.703,165.106z"/> </g> </svg> </a> <a title="Share on X" class="flex items-center gap-2 p-4 border rounded-full hover:bg-gray-100 transition" target="_blank" href="http://twitter.com/intent/tweet?text=Listening+to+%222022%27s+Biggest+Antitrust+Developments+and+What+to+Expect+in+2023%22+at+&url=https%3A%2F%2Fwww.buzzsprout.com%2F221709%2Fepisodes%2F12104405"> <svg viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg" class="w-4 h-4"> <path d="M13.6468 10.4686L20.9321 2H19.2057L12.8799 9.3532L7.82741 2H2L9.64031 13.1193L2 22H3.72649L10.4068 14.2348L15.7425 22H21.57L13.6464 10.4686H13.6468ZM11.2821 13.2173L10.508 12.1101L4.34857 3.29968H7.00037L11.9711 10.4099L12.7452 11.5172L19.2066 20.7594H16.5548L11.2821 13.2177V13.2173Z" fill=""/> </svg> </a> <a title="Share on LinkedIn" class="flex items-center gap-2 p-4 border rounded-full hover:bg-gray-100 transition" target="_blank" href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.buzzsprout.com%2F221709%2Fepisodes%2F12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023"> <svg viewBox="0 0 19 18" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" class="w-4 h-4"> <g id="Linkedin" stroke="none" stroke-width="1" fill-rule="evenodd"> <g id="Linkedin" transform="translate(-272.000000, -45.000000)"> <g id="Linkedin" transform="translate(272.000000, 45.000000)"> <polygon id="Path" points="4.27540224 5.71779313 0.238700218 5.71779313 0.238700218 17.5787127 4.27540224 17.5787127"></polygon> <path d="M4.54126962,2.0487322 C4.51506984,0.885776552 3.66466504,1.42108547e-14 2.28373471,1.42108547e-14 C0.902804369,1.42108547e-14 1.13686838e-13,0.885776552 1.13686838e-13,2.0487322 C1.13686838e-13,3.18759902 0.876120893,4.0988814 2.23133513,4.0988814 L2.25713184,4.0988814 C3.66466504,4.0988814 4.54126962,3.18759902 4.54126962,2.0487322 Z" id="Path"></path> <path d="M18.833294,10.7780239 C18.833294,7.13486242 16.8418683,5.43927576 14.1855323,5.43927576 C12.0423091,5.43927576 11.0827519,6.59050188 10.5469864,7.39810778 L10.5469864,5.71810802 L6.50980073,5.71810802 C6.56300646,6.83107539 6.50980073,17.5790276 6.50980073,17.5790276 L10.5469864,17.5790276 L10.5469864,10.9549116 C10.5469864,10.6004278 10.5731862,10.2468099 10.6799201,9.99301113 C10.9716648,9.28483073 11.6359302,8.55161683 12.7511544,8.55161683 C14.2124576,8.55161683 14.796592,9.63923582 14.796592,11.233114 L14.796592,17.5787127 L18.8331328,17.5787127 L18.833294,10.7780239 Z" id="Path"></path> </g> </g> </g> </svg> </a> </div> <div class="mt-10"> <div class="w-full flex items-center mt-3 py-2 px-2 border border-gray-200 rounded-md focus-within:ring-1"> <input type="text" name="share_url" id="share_url" value="https://www.buzzsprout.com/221709/episodes/12104405" class="w-full py-2 px-3 border-0 focus:ring-0 bg-transparent" data-timestamp-target="url" /> <button data-action="timestamp#copy" class="py-2.5 px-4 text-sm text-white font-semibold bg-[--primary-color] rounded-md whitespace-nowrap">Copy</button> </div> <div class="flex items-center mt-4"> <input type="checkbox" name="start_at" id="start_at" value="" class="border border-gray-200 rounded-md focus-within:ring-1 p-3.5" data-action="input->timestamp#update" data-timestamp-target="checkbox" /> <label class="ml-3 whitespace-nowrap" for="start_at">Start at</label> <input type="text" name="time" id="time" value="00:00" data-action="input->timestamp#update" data-timestamp-target="time" disabled="disabled" class="relative top-[1px] ml-2 p-0 text-gray border-none" /> </div> </div> </div> </div> </div> </dialog> </div> </div> <div> <div class="pt-8" data-controller="player"> <div data-controller="players--small" data-players--small-style-value="custom-wave" data-players--small-features-value='["progress", "current", "duration"]' data-action="media-player:canplay@document->players--small#autoPlay" class="group [&_.mejs-offscreen]:sr-only"> <div class="flex gap-2 items-center"> <button data-players--small-target="playButton" data-action='players--small#togglePlay' type="button" title="Play" aria-label="Play/Pause" class="group rounded-full p-5 flex items-center justify-center playpause-button bg-[--primary-color]"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="w-10 h-10 group-[.is-playing]:!hidden fill-white relative left-0.5 hover:opacity-70"> <path fill-rule="evenodd" d="M4.5 5.653c0-1.427 1.529-2.33 2.779-1.643l11.54 6.347c1.295.712 1.295 2.573 0 3.286L7.28 19.99c-1.25.687-2.779-.217-2.779-1.643V5.653Z" clip-rule="evenodd" /> </svg> <svg aria-hidden="true" xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" class="w-10 h-10 hidden group-[.is-playing]:block fill-white"> <path fill-rule="evenodd" d="M8 5a2 2 0 0 0-2 2v10a2 2 0 0 0 2 2h1a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2H8Zm7 0a2 2 0 0 0-2 2v10a2 2 0 0 0 2 2h1a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2h-1Z" clip-rule="evenodd"/> </svg> </button> <div class="custom-wave-form w-full h-12 relative top-1" style="background-image: url('https://www.buzzsprout.com/player/wave/5'); background-repeat: no-repeat;"> <audio src="https://www.buzzsprout.com/221709/episodes/12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023.mp3?client_source=buzzsprout_website&referrer=https%3A%2F%2Fahlapodcasts.buzzsprout.com%2F221709%2Fepisodes%2F12104405-2022-s-biggest-antitrust-developments-and-what-to-expect-in-2023" class="mejs-buzz" type="audio/mp3" controls="controls" width="100%" preload="none" data-players--small-target="audio" data-player-target="audio" data-hide-play-pause-button="true" data-duration="3554" data-episode-id="12104405" data-episode-title="2022's Biggest Antitrust Developments and What to Expect in 2023" data-podcast-artist="AHLA Podcasts" data-podcast-title="AHLA's Speaking of Health Law" data-episode-artwork="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDam9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFuZ0ZhUUo0QlhzR09nbGpjbTl3T2d0alpXNTBjbVU2RUdSbFptRjFiSFJmZFhKc1NTSTVhSFIwY0hNNkx5OTNkM2N1WW5WNmVuTndjbTkxZEM1amIyMHZhVzFoWjJWekwyRnlkSGR2Y210elgyeGhjbWRsTG1wd1p3WTZCa1ZVT2dwellYWmxjbnNHT2d4eGRXRnNhWFI1YVVFNkVHTnZiRzkxY25Od1lXTmxTU0lKYzNKbllnWTdDMVE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--2a89ede784d6e184500689d6dcbd55b204c8d4ad/AHLA_Buzzsprout.jpg" data-episode-medium-artwork="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFsZ0NhUUpZQW5zR09nbGpjbTl3T2d0alpXNTBjbVU2Q25OaGRtVnlld1k2REhGMVlXeHBkSGxwUVRvUVkyOXNiM1Z5YzNCaFkyVkpJZ2x6Y21kaUJqb0dSVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--1924d851274c06c8fa0acdfeffb43489fc4a7fcc/AHLA_Buzzsprout.jpg" data-episode-small-artwork="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDVG9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFmcHBBZnA3QmpvSlkzSnZjRG9MWTJWdWRISmxPZ3B6WVhabGNuc0dPZ3h4ZFdGc2FYUjVhVUU2RUdOdmJHOTFjbk53WVdObFNTSUpjM0puWWdZNkJrVlUiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--bfdad5b04912fa8a9db85eb3989e46c5908e2723/AHLA_Buzzsprout.jpg"></audio> </div> </div> <div class="flex items-center gap-2 pt-3 px-2.5"> <button data-action="players--small#rewind" class="controls-button icon-rewind" aria-label="Rewind 15 seconds"> <svg width="28" height="28" viewBox="0 0 28 28" fill="none" xmlns="http://www.w3.org/2000/svg"> <g clip-path="url(#clip0_597_182)"> <path d="M11.7331 5.02519C11.3312 5.12558 10.9241 4.88118 10.8237 4.47932C10.7233 4.07746 10.9677 3.6703 11.3696 3.56991L11.7331 5.02519ZM17.1313 4.29303L17.3119 3.5651L17.3127 3.5653L17.1313 4.29303ZM22.7001 7.66158L23.2605 7.16308L23.2614 7.16415L22.7001 7.66158ZM25.3454 13.5545L26.0902 13.4656L26.0903 13.4664L25.3454 13.5545ZM24.1853 19.9886L24.8525 20.3312L24.8525 20.3312L24.1853 19.9886ZM10.9484 26.0337L11.1259 25.305L11.1264 25.3051L10.9484 26.0337ZM2.69045 14.5853L1.94297 14.5238L1.94299 14.5236L2.69045 14.5853ZM4.51243 7.99796C4.76893 7.67272 5.24053 7.617 5.56576 7.87351C5.891 8.13001 5.94671 8.60161 5.69021 8.92684L4.51243 7.99796ZM12.0777 4.83186C11.7826 5.12254 11.3077 5.11896 11.017 4.82387C10.7263 4.52877 10.7299 4.05391 11.025 3.76324L12.0777 4.83186ZM14.3208 0.516822C14.6159 0.226146 15.0907 0.229727 15.3814 0.52482C15.6721 0.819914 15.6685 1.29477 15.3734 1.58545L14.3208 0.516822ZM11.0252 4.832C10.73 4.5414 10.7263 4.06654 11.0169 3.77137C11.3075 3.4762 11.7823 3.4725 12.0775 3.7631L11.0252 4.832ZM15.2871 6.92302C15.5823 7.21362 15.586 7.68847 15.2954 7.98364C15.0048 8.27881 14.53 8.28252 14.2348 7.99192L15.2871 6.92302ZM11.3696 3.56991C13.3202 3.08262 15.3605 3.08097 17.3119 3.5651L16.9507 5.02096C15.2373 4.59588 13.4458 4.59733 11.7331 5.02519L11.3696 3.56991ZM17.3127 3.5653C19.6123 4.13849 21.6853 5.39244 23.2605 7.16308L22.1398 8.16009C20.7653 6.61508 18.9565 5.52092 16.9499 5.02076L17.3127 3.5653ZM23.2614 7.16415C24.8242 8.9275 25.8111 11.1261 26.0902 13.4656L24.6007 13.6433C24.3578 11.6071 23.4989 9.69369 22.1388 8.15902L23.2614 7.16415ZM26.0903 13.4664C26.3692 15.8268 25.9383 18.2169 24.8525 20.3312L23.5181 19.6459C24.4677 17.7969 24.8446 15.7068 24.6006 13.6425L26.0903 13.4664ZM24.8525 20.3312C22.2111 25.4741 16.387 28.1339 10.7705 26.7623L11.1264 25.3051C16.0687 26.5121 21.1938 24.1715 23.5182 19.6459L24.8525 20.3312ZM10.771 26.7624C5.21828 25.41 1.47425 20.2196 1.94297 14.5238L3.43792 14.6469C3.02973 19.6071 6.29027 24.1273 11.1259 25.305L10.771 26.7624ZM1.94299 14.5236C2.1396 12.1432 3.0333 9.87342 4.51243 7.99796L5.69021 8.92684C4.39364 10.5708 3.61024 12.5604 3.4379 14.6471L1.94299 14.5236ZM11.025 3.76324L14.3208 0.516822L15.3734 1.58545L12.0777 4.83186L11.025 3.76324ZM12.0775 3.7631L15.2871 6.92302L14.2348 7.99192L11.0252 4.832L12.0775 3.7631Z" fill="black"/> <path d="M10.9275 18.7299V13.253H10.8507L9.21032 14.4234V13.4292L10.9275 12.2091H11.9398V18.7299H10.9275ZM15.8624 18.8881C14.579 18.8881 13.6933 18.0882 13.6029 17.0308L13.5984 16.9721H14.5474L14.5519 17.0082C14.6378 17.5821 15.1575 18.0385 15.8714 18.0385C16.6758 18.0385 17.2362 17.4646 17.2362 16.6467V16.6377C17.2362 15.8333 16.6668 15.2639 15.8805 15.2639C15.4828 15.2639 15.1439 15.3814 14.8863 15.6164C14.7688 15.7203 14.6649 15.8468 14.5881 15.996H13.7159L14.0413 12.2091H17.8327V13.0677H14.8366L14.6378 15.1464H14.7146C14.9903 14.7081 15.5009 14.455 16.1019 14.455C17.3266 14.455 18.2032 15.3678 18.2032 16.6196V16.6286C18.2032 17.9662 17.2362 18.8881 15.8624 18.8881Z" fill="black"/> </g> <defs> <clipPath id="clip0_597_182"> <rect width="28" height="28" fill="white"/> </clipPath> </defs> </svg> </button> <button data-action="players--small#forward" class="controls-button icon-forward" aria-label="Forward 30 seconds"> <svg width="28" height="28" viewBox="0 0 28 28" fill="none" xmlns="http://www.w3.org/2000/svg"> <g clip-path="url(#clip0_597_191)"> <path d="M15.9968 5.02519C16.3987 5.12558 16.8058 4.88118 16.9062 4.47932C17.0066 4.07746 16.7622 3.6703 16.3604 3.56991L15.9968 5.02519ZM10.5986 4.29303L10.418 3.5651L10.4172 3.5653L10.5986 4.29303ZM5.02978 7.66158L4.46943 7.16308L4.46848 7.16415L5.02978 7.66158ZM2.38449 13.5545L1.63977 13.4656L1.63968 13.4664L2.38449 13.5545ZM3.54462 19.9886L2.87746 20.3312L2.87747 20.3312L3.54462 19.9886ZM16.7815 26.0337L16.604 25.305L16.6036 25.3051L16.7815 26.0337ZM25.0395 14.5853L25.787 14.5238L25.7869 14.5236L25.0395 14.5853ZM23.2175 7.99796C22.961 7.67272 22.4894 7.617 22.1642 7.87351C21.8389 8.13001 21.7832 8.60161 22.0397 8.92684L23.2175 7.99796ZM15.6523 4.83186C15.9474 5.12254 16.4222 5.11896 16.7129 4.82387C17.0036 4.52877 17 4.05391 16.7049 3.76324L15.6523 4.83186ZM13.4092 0.516822C13.1141 0.226146 12.6392 0.229727 12.3485 0.52482C12.0579 0.819914 12.0614 1.29477 12.3565 1.58545L13.4092 0.516822ZM16.7048 4.832C16.9999 4.5414 17.0036 4.06654 16.713 3.77137C16.4224 3.4762 15.9476 3.4725 15.6524 3.7631L16.7048 4.832ZM12.4428 6.92302C12.1476 7.21361 12.1439 7.68847 12.4345 7.98364C12.7251 8.27881 13.2 8.28252 13.4951 7.99192L12.4428 6.92302ZM16.3604 3.56991C14.4097 3.08262 12.3694 3.08097 10.418 3.5651L10.7792 5.02096C12.4926 4.59588 14.2841 4.59733 15.9968 5.02519L16.3604 3.56991ZM10.4172 3.5653C8.11764 4.13849 6.04465 5.39244 4.46943 7.16308L5.59013 8.16009C6.96463 6.61508 8.77346 5.52092 10.78 5.02076L10.4172 3.5653ZM4.46848 7.16415C2.90577 8.9275 1.91885 11.1261 1.63977 13.4656L3.12921 13.6433C3.3721 11.6071 4.23103 9.69369 5.59108 8.15902L4.46848 7.16415ZM1.63968 13.4664C1.36068 15.8268 1.79163 18.2169 2.87746 20.3312L4.21178 19.6459C3.26219 17.7969 2.88532 15.7068 3.12931 13.6425L1.63968 13.4664ZM2.87747 20.3312C5.51882 25.4741 11.343 28.1339 16.9594 26.7623L16.6036 25.3051C11.6612 26.5121 6.5361 24.1715 4.21178 19.6459L2.87747 20.3312ZM16.959 26.7624C22.5116 25.41 26.2557 20.2196 25.787 14.5238L24.292 14.6469C24.7002 19.6071 21.4397 24.1273 16.604 25.305L16.959 26.7624ZM25.7869 14.5236C25.5903 12.1432 24.6966 9.87342 23.2175 7.99796L22.0397 8.92684C23.3363 10.5708 24.1197 12.5604 24.292 14.6471L25.7869 14.5236ZM16.7049 3.76324L13.4092 0.516822L12.3565 1.58545L15.6523 4.83186L16.7049 3.76324ZM15.6524 3.7631L12.4428 6.92302L13.4951 7.99192L16.7048 4.832L15.6524 3.7631Z" fill="black"/> <path d="M10.9701 18.8519C9.57822 18.8519 8.66991 18.0882 8.58405 17.0082L8.57953 16.954H9.54658L9.5511 16.9992C9.61437 17.5912 10.1612 18.0069 10.9701 18.0069C11.7654 18.0069 12.3032 17.5595 12.3032 16.9178V16.9088C12.3032 16.1722 11.7699 15.761 10.9023 15.761H10.1069V14.9747H10.8706C11.6163 14.9747 12.1224 14.5363 12.1224 13.9308V13.9218C12.1224 13.2891 11.6976 12.9186 10.961 12.9186C10.238 12.9186 9.73186 13.3027 9.6686 13.9172L9.66408 13.9624H8.7151L8.71961 13.9127C8.81903 12.8146 9.68667 12.0871 10.961 12.0871C12.258 12.0871 13.1075 12.783 13.1075 13.7907V13.7997C13.1075 14.6086 12.5291 15.1509 11.7338 15.3181V15.3407C12.6918 15.4266 13.3335 16.005 13.3335 16.9178V16.9269C13.3335 18.0476 12.3529 18.8519 10.9701 18.8519ZM16.7184 18.8881C15.2135 18.8881 14.3097 17.5731 14.3097 15.4718V15.4627C14.3097 13.3614 15.2135 12.0509 16.7184 12.0509C18.2187 12.0509 19.127 13.3614 19.127 15.4627V15.4718C19.127 17.5731 18.2187 18.8881 16.7184 18.8881ZM16.7184 18.0476C17.5905 18.0476 18.1057 17.067 18.1057 15.4718V15.4627C18.1057 13.8675 17.5905 12.896 16.7184 12.896C15.8417 12.896 15.331 13.8675 15.331 15.4627V15.4718C15.331 17.067 15.8417 18.0476 16.7184 18.0476Z" fill="black"/> </g> <defs> <clipPath id="clip0_597_191"> <rect width="28" height="28" fill="white"/> </clipPath> </defs> </svg> </button> <button data-action="players--small#changeSpeed" class="group icon-speed-1" aria-label="Change playback speed"> <svg width="40" height="28" viewBox="0 0 40 28" fill="none" xmlns="http://www.w3.org/2000/svg" class="hidden group-[.icon-speed-1]:block"> <path d="M15.2621 20V9.921H15.1162L12 12.0748V10.2453L15.2621 8H17.1851V20H15.2621Z" fill="black"/> <path d="M20.708 11.8315L21.6719 10.8906L24.3503 13.5494L27.0287 10.8906L28 11.8315L25.3142 14.5045L28 17.1704L27.0287 18.1184L24.3503 15.4597L21.6719 18.1184L20.708 17.1704L23.3938 14.5045L20.708 11.8315Z" fill="black"/> </svg> <svg width="40" height="28" viewBox="0 0 40 28" xmlns="http://www.w3.org/2000/svg" class="hidden group-[.icon-speed-125]:block"> <path d="M8.16458 20.0085V9.91521H8.02301L5 12.0721V10.24L8.16458 7.99148H10.03V20.0085H8.16458Z" fill="black"/> <path d="M13.0527 20.1334C12.3615 20.1334 11.8285 19.6005 11.8285 18.9259C11.8285 18.2431 12.3615 17.7101 13.0527 17.7101C13.7439 17.7101 14.2686 18.2431 14.2686 18.9259C14.2686 19.6005 13.7439 20.1334 13.0527 20.1334Z" fill="black"/> <path d="M17.4174 20.0085V18.7427L21.4066 14.5538C22.9971 12.8966 23.4552 12.2803 23.4552 11.306V11.281C23.4552 10.1067 22.6474 9.24065 21.3316 9.24065C19.9825 9.24065 19.083 10.1234 19.083 11.4392L19.0747 11.4642H17.3259L17.3092 11.4475C17.3176 9.24897 19.0164 7.7 21.4315 7.7C23.6717 7.7 25.3206 9.12406 25.3206 11.1061V11.1311C25.3206 12.4968 24.6877 13.5461 22.5058 15.7114L19.9575 18.2514V18.4179H25.5121V20.0085H17.4174Z" fill="black"/> <path d="M31.7833 20.3C29.4182 20.3 27.786 18.826 27.6194 16.8773L27.6111 16.769H29.3599L29.3683 16.8356C29.5264 17.8933 30.4842 18.7344 31.8 18.7344C33.2823 18.7344 34.315 17.6767 34.315 16.1694V16.1527C34.315 14.6704 33.2657 13.6211 31.8166 13.6211C31.0838 13.6211 30.4592 13.8376 29.9845 14.2707C29.768 14.4622 29.5765 14.6954 29.4349 14.9702H27.8276L28.4272 7.99148H35.4143V9.57377H29.8929L29.5264 13.4046H29.668C30.176 12.5968 31.1171 12.1304 32.2247 12.1304C34.4815 12.1304 36.0971 13.8126 36.0971 16.1195V16.1361C36.0971 18.6011 34.315 20.3 31.7833 20.3Z" fill="black"/> </svg> <svg width="40" height="28" viewBox="0 0 40 28" xmlns="http://www.w3.org/2000/svg" class="hidden group-[.icon-speed-15]:block"> <path d="M13.1646 20.0085V9.91521H13.023L10 12.0721V10.24L13.1646 7.99148H15.03V20.0085H13.1646Z" fill="black"/> <path d="M18.0527 20.1334C17.3615 20.1334 16.8285 19.6005 16.8285 18.9259C16.8285 18.2431 17.3615 17.7101 18.0527 17.7101C18.7439 17.7101 19.2686 18.2431 19.2686 18.9259C19.2686 19.6005 18.7439 20.1334 18.0527 20.1334Z" fill="black"/> <path d="M24.7833 20.3C22.4182 20.3 20.786 18.826 20.6194 16.8773L20.6111 16.769H22.3599L22.3683 16.8356C22.5264 17.8933 23.4842 18.7344 24.8 18.7344C26.2823 18.7344 27.315 17.6767 27.315 16.1694V16.1527C27.315 14.6704 26.2657 13.6211 24.8166 13.6211C24.0838 13.6211 23.4592 13.8376 22.9845 14.2707C22.768 14.4622 22.5765 14.6954 22.4349 14.9702H20.8276L21.4272 7.99148H28.4143V9.57377H22.8929L22.5264 13.4046H22.668C23.176 12.5968 24.1171 12.1304 25.2247 12.1304C27.4815 12.1304 29.0971 13.8126 29.0971 16.1195V16.1361C29.0971 18.6011 27.315 20.3 24.7833 20.3Z" fill="black"/> </svg> <svg width="40" height="28" viewBox="0 0 40 28" xmlns="http://www.w3.org/2000/svg" class="hidden group-[.icon-speed-2]:block"> <path d="M21.3974 11.8315L22.3613 10.8906L25.0397 13.5494L27.7181 10.8906L28.6894 11.8315L26.0036 14.5045L28.6894 17.1704L27.7181 18.1184L25.0397 15.4597L22.3613 18.1184L21.3974 17.1704L24.0832 14.5045L21.3974 11.8315Z" fill="black"/> <path d="M11.1061 19.9647V18.7243L15.0152 14.6193C16.5739 12.9953 17.0227 12.3914 17.0227 11.4366V11.4121C17.0227 10.2614 16.2311 9.41268 14.9417 9.41268C13.6196 9.41268 12.7383 10.2777 12.7383 11.5672L12.7301 11.5916H11.0163L11 11.5753C11.0082 9.42083 12.673 7.90291 15.0396 7.90291C17.2349 7.90291 18.8508 9.29843 18.8508 11.2407V11.2652C18.8508 12.6036 18.2306 13.6319 16.0924 15.7537L13.5952 18.2428V18.406H19.0385V19.9647H11.1061Z" fill="black"/> </svg> </button> </div> </div> <div class="pt-8" data-controller="tabs" data-tabs-hide-class="hidden" data-tabs-active-class="!border-b-[--primary-color] border-b-4"> <ul class="tabs relative shadow-[inset_0_-1px_0_0] shadow-gray-200 flex gap-6"> <li class=""> <button name="button" type="submit" id="show-notes-tab" role="tab" aria-selected="true" data-tabs-target="tab" data-tab-toggle-panel="show-notes-panel" data-action="click->tabs#toggle" class="py-2 px-1 whitespace-nowrap relative z-1">Show Notes</button> </li> <li class="hidden"> <button name="button" type="submit" id="chapters-tab" role="tab" aria-selected="false" data-tabs-target="tab" data-tab-toggle-panel="chapters-panel" data-action="click->tabs#toggle" class="py-2 px-1">Chapters</button> </li> <li class=""> <button name="button" type="submit" id="transcript-tab" role="tab" aria-selected="false" data-tabs-target="tab" data-tab-toggle-panel="transcript-panel" data-action="click->tabs#toggle" class="py-2 px-1">Transcript</button> </li> </ul> <div class="mt-8"> <div id="show-notes-panel" class="show-notes" role="tabpanel" aria-labelledby="show-notes-tab" tabindex="0" dir="auto" data-controller="convert-links-to-open-in-new-tab" data-tabs-target="panel" data-tabs-panel="show-notes-panel"> <p>In the fifth installment of their popular annual series, John D. Carroll, Partner, Sheppard Mullin Richter & Hampton LLP, and Alexis J. Gilman, Partner, Crowell and Moring LLP, are joined by Peter Herrick, Partner, Axinn Veltrop & Harkrider LLP, to discuss 2022's biggest antitrust developments and what attorneys should expect in 2023. Sponsored by <a href="https://www.axinn.com/">Axinn</a>.</p><p>To learn more about AHLA and the educational resources available to the health law community, visit <a href="https://www.americanhealthlaw.org/">americanhealthlaw.org</a>.</p> </div> <div id="transcript-panel" class="transcript" role="tabpanel" aria-labelledby="transcript-tab" tabindex="0" dir="auto" data-tabs-target="panel" data-tabs-panel="transcript-panel" class="hidden"> <cite>Speaker 1:</cite> <time>0:14</time> <p>Support for A H L A comes from Axinn, which brings unmatched depth in the skills needed to address healthcare, collaboration, and competition. They are one of the best known antitrust firms in the world with more than 60 full-time competition lawyers. They represent companies across the healthcare universe and help clients avoid antitrust landmines, complete mission critical deals, and protect their interests and litigation and investigations. For from my information, visit axon.com.</p> <cite>Speaker 2:</cite> <time>0:43</time> <p>Welcome to the ALA's Antitrust Year in Review Review podcast for 22. My name is Pete Harrick. I'm a partner in the New York Offices of Axon, Vero Andry, and I'm very pleased on behalf of Axon to be sponsoring this podcast. With me today are two esteemed members of the Antitrust Bar, Alexis Gilman and John Carroll. To those who are familiar with these podcasts, you will no doubt recognize Alexis and John from years of hosting these annual reviews, which I think now go back five years running. Uh, today we are bringing you, uh, the top 10 antitrust healthcare developments from 2022 and the top 10 things to watch for in 2023. So, without further ado, I'll let Alexis and John introduce themselves.</p> <cite>Speaker 3:</cite> <time>1:37</time> <p>Thanks, Pete. It's Alexis. Uh, I'm a partner in the Antitrust in Competition Group at Kroll and Mooring in Washington, DC.</p> <cite>Speaker 4:</cite> <time>1:45</time> <p>Hey, Alexis, happy New Year. Uh, good to be doing this with you again. Uh, John Carroll. Uh, I'm a partner in the, uh, antitrust competition practice here at Shepherd Mullin and also in Washington DC</p> <cite>Speaker 3:</cite> <time>1:58</time> <p>And thanks to Pete for, uh, moderating this this year.</p> <cite>Speaker 2:</cite> <time>2:02</time> <p>My pleasure. All right. Uh, well, since all of us work in the world of antitrust and healthcare, we do need to put out the obligatory disclaimer that the views we express here are our own and are not those of any of our clients or our firm's clients. Uh, so just to start things off, one of the real challenges, uh, this is my first time doing this year in review, uh, is actually narrowing down the lists, uh, to 10, uh, because there's so much going on in the world of healthcare and antitrust, but Alexis and John have done their best, uh, so to keep everyone on the edge of their seats, we're going to do this in a sort of round robin alternating style and countdown to the number one biggest development in 2022, and the number one thing to watch for in 2023. So, starting in 2022, what was the number 10 biggest development in antitrust healthcare? To answer that question, I'm gonna hand it off to John.</p> <cite>Speaker 4:</cite> <time>3:06</time> <p>Thanks so much, Pete. Um, and as you said, it's been tough to narrow it down and there's a lot to cover, so, we'll, we'll go through these at a high level. Um, we<laugh> have determined that the number 10, uh, most interesting or important, whatever you wanna call it, development and healthcare antitrust in 2022, was the, uh, fact that the F T C scrutinized closely, but ultimately cleared, uh, the, uh, transaction between advocates, uh, Aurora Health, uh, and Atrium Health. Uh, as folks may know, uh, this was one of the largest provider healthcare transactions, I think, in US history. 67 hospitals, 27 billion transaction. Uh, the FTC took a very close look at it according to, uh, publicly available sources, and, uh, ultimately cleared the transaction toward the end of last year. Um, the interesting part about this, purely from an antitrust perspective, was that advocate, uh, Aurora operates principally in the Midwest and Atrium, principally in the Southeast. And so there wasn't geographic overlap or geographic, I guess you could say, competition between the two systems. But it nevertheless, um, uh, got a, a, a very close look by the ftc, similar to that of, of Spectrum Beaumont, um, back a, a a little ways in Michigan. And if the FTC had challenged it, I believe it would've been the first, um, so-called cross market, uh, healthcare merger or hospital merger to be challenged, uh, by the ftc Pete.</p> <cite>Speaker 2:</cite> <time>4:40</time> <p>Okay, well, staying in the Southeast, uh, we're gonna shift over to North Carolina to talk about, uh, some local, uh, challenges to a healthcare deal, uh, to talk about that. Um, I'm gonna hand it off to Alexis.</p> <cite>Speaker 3:</cite> <time>4:55</time> <p>Thanks, Pete. So, um, this one has a pretty interesting history that goes back ways. Um, but the upshot is that last fall, late summer, maybe two counties in, uh, uh, two cities in North Carolina sued, uh, in a class action lawsuit, H C A and its subsidiary Mission Health for allegedly violating the Sherman Act. And this case, like I said, goes back, um, to the mid nineties where a hospital merger created mission health system pursuant to a Certificate of Public Advantage or copa. We'll be talking more about those, uh, later, later in the podcast. But basically, that COPA gave that merger antitrust immunity from, from federal Antitrust Challenge, and that COPA lasted for 20 years until North Carolina appealed its COPA Law, uh, in 2015 and later, um, H c a acquired mission. So basically, in August, these cities and counties in North Carolina filed this suit against H c a admissions saying that missions contracting practices with payers violated, uh, antitrust laws. Uh, basically they said that, uh, mission had these all or nothing tying contracts that required health plans to contract with all mission general acute care hospitals and outpatient service providers, uh, in a single bundle, or none at all, that it had anti steering and anti tiering, uh, provisions in its contract with payers. And it had gag clauses that prevented payers from telling employers and patients about the prices of, of healthcare services. And there are some other things thrown into the allegations, but these are similar claims, uh, as were raised by the DO O j North Carolina Ag against Atrium Health a few years ago. And that case was settled and, uh, similar to some claims we'll talk about later as well against Sutter Health. But at any rate, mission said, you know, look, we were granted a, a lawful monopoly, basically, or monopoly positioned through this COPA with state approval. So you can't show that we unlawfully obtain a monopoly or maintain that monopoly. And in any case, plaintiffs have failed to, um, show that these contractual provisions, uh, allegedly led to the monopoly or harm competition in any way. So, it's a pretty significant case because the F T E C and other interest forces have long complained about CO's, um, and have worried about what happens when those copas go away, and you have this consolidated provider, um, and can anything be done after the fact? So we may get some answers, uh, to those questions coming out of this case.</p> <cite>Speaker 2:</cite> <time>7:30</time> <p>Thanks, Alexis. And, and this, this concept of the owner nothing contracting is, is, as you previewed going to come up again. And it, it does seem that this is an area where antitrust enforcers are really focusing their energies. So I'm sure there, there's going to be more to that, uh, in the coming year and and beyond. Um, switching over to criminal, uh, antitrust, uh, John, uh, number eight is going to talk about generics.</p> <cite>Speaker 4:</cite> <time>8:05</time> <p>Thanks. I'm glad you didn't, you didn't just allude to my being a criminal<laugh>, speaking of being a criminal. John Carroll's gonna talk now.</p> <cite>Speaker 3:</cite> <time>8:14</time> <p><laugh>.</p> <cite>Speaker 4:</cite> <time>8:15</time> <p>Yeah, this has been, uh, thanks, Pete. This has been, uh, for those of you who are, are, uh, repeat listeners to the, uh, top 10 Antitrust Healthcare podcast we've been doing now for several years. I think we've covered this just about every year because there's something going on, um, in this sprawling, uh, not case, but this sprawling matter. Um, uh, and, and that's been the case really, I think for now, seven or eight years since the first round of indictments. Um, the generic pharmaceutical industry has been, um, subject to a number of, um, complaints, indictments and, and, uh, massive m d l in the space concerning alleged price fixing with respect to number of generic drugs. Um, 2022 had a number of developments, um, certainly in the criminal arena, also in the M D L. Uh, the main, uh, uh, development in terms of the Department of Justice's, uh, criminal action, uh, was, uh, a few things that just happened with respect to the, uh, the case they're bringing in the Eastern District of Pennsylvania, where they indicted, uh, Glen Mark and I believe it's Teva as a, as a co-conspirator. Um, uh, nothing too, uh, crazy that happened, but, uh, too, too, uh, interesting that happened. But a couple of things moved along with respect to scheduling order, uh, rounding out some witnesses, I think, um, that are supposed to be, or some testimony rather that's supposed to be finishing up, um, this year. And according to the judge, an enormous volume of complex discovery in the case, more than 22 million documents counting, I think as of earlier in 2022. Um, there, uh, th this continues to move relatively, uh, slowly. So we'll, we'll continue to keep our eye on this, both the criminal trial, uh, and of course, developments in the M D L and, and very well maybe, uh, having an update, uh, a year from now if we do this podcast again on this topic. Um, the other thing I'll say is more broadly, um, the investigation, the DOJ investigation and, and, and action. And of course, the litigation have brought a lot of attention to the industry. And so there have been calls from, you know, US House of Representatives committee on oversight and drug pricing. There's been legislation that's been, um, put together. I don't think any of it has passed with respect to pharmaceutical pricing. And so this is all part of, um, the bigger topic of drug pricing in the United States and sort of what role and, uh, that the, uh, at the antitrust plays, um, with respect to that issue.</p> <cite>Speaker 2:</cite> <time>10:54</time> <p>Yeah. And John, uh, thank you for that. I certainly didn't mean to imply that, uh, you have any specific criminal background, but, uh, I appreciate you clarifying that for the record. Uh, so, uh, and I agree, I think the, uh, the, the broad, uh, interest in pharma pricing is definitely picking up steam at both agencies. And we're gonna talk in a minute about, uh, PBMs and their role in that, in, in setting pricing and, and the effect of PBMs on, um, overall prices in pharma. But before we get to that, uh, we are going to go back to Alexis to talk about Sutter Health.</p> <cite>Speaker 3:</cite> <time>11:39</time> <p>Yeah, there's another long running case, uh, this, this one running a decade long against Sutter Health. Um, this, uh, is a federal class action that, um, raised some allegations that were, were pretty similar to, um, a settlement that are entered into with the California Ag about a year ago that I think also appeared on our last year's podcast. But in March in a case called C Bay, and John and Pete, correct me if I'm not saying that right, C Bay versus Sutter Health. Uh, uh, a grand or a jury in California, not a grand jury, a jury in California returned a verdict for Sutter, um, on a class action brought by health plan subscribers who claimed that Sutter was unlawfully tying its hospitals, hospitals that were must have in some areas with hospitals in other areas that were in more competitive areas and required payers to contract with all of the center hospitals or none. Again, this all or nothing, uh, contract term that we previously talked about in North Carolina, and also by preventing payers from, um, steering patients to lower cost hospitals. And so the, the plaintiffs in this case said that the, the ultimate effect of these provisions was to raise prices for health plan subscribers. And the plaintiffs were looking for over 400 million in damages. Um, Sutter basically said, you know, look, we face a lot of competition and we don't have market power, and we didn't use any alleged market power to tie the services of our hospitals together. Um, as I, as I mentioned, these are pretty similar claims to ones made by the California Ag and other PLI plaintiffs in a state case against Sutter that settled last year. Um, and in that case, Sutter agreed to pay 575 million, um, to the plaintiffs and to end its all or nothing contracting terms and steering contracting terms, and allow prices to be shared with health plan members, um, in this federal case. Um, like I said, the, the jury trying to verdict in Sutter's favor, the plaintiffs have appealed, uh, that decision to the ninth Circuit. So, uh, we haven't heard the last one, uh, last of this one either. And so we're, we're probably picking up, uh, perhaps next year's, uh, update, Pete.</p> <cite>Speaker 2:</cite> <time>13:56</time> <p>Yeah, that is definitely one to watch going forward. Notwithstanding the long and tortured history of that case, it's still, uh, unresolved amazingly. Um, so at number six, uh, we're going to turn back to John to talk about, uh, the F FTC COPA policy paper.</p> <cite>Speaker 4:</cite> <time>14:18</time> <p>Sure. Thanks. And Alexis, um, talked a bit about this with respect to number nine and the litigation, um, and certificates of public advantage. So back in, um, on August 15th, the Federal Trade Commission, uh, issued a policy paper, uh, on, on CPA's, certificates of Public Advantage, um, that was issued on a a five to zero, uh, vote with all commissioners, um, uh, in favor of the policy statement that the FTC put forth at bottom, the Ft. C's position is that the COPA s um, certifi, again, certificate of Public Certificates of public Advantage, um, issued by states are essentially laws that are enacted, um, to shield hospital mergers from the antitrust laws in favor of state oversight. So the paper and the accompanying, uh, fact sheet that the F T C put forth, you know, details, the research that they had undertaken since I believe it's 2017, um, purporting to demonstrate that COPA S are detrimental, uh, for, according to the FTC patient costs, patient care and healthcare worker wages. Also, the ftc, uh, alleges in the policy paper, um, that most, I'm quoting here, most of the cos that have been approved so far have resulted in a single hospital monopoly. And there's a footnote that cite a few examples to that. So this came out, um, in August, uh, making clear what the Ft C's position is. And as Alexis, um, mentioned just a few minutes ago, um, there's been, uh, litigation, uh, private litigation about the extent to which COPA policies have shielded transactions, and for how long have they shielded them, uh, from monopolization claims and other antitrust claims, uh, again, in private litigation. So this is definitely a space to follow. Um, we'll see how influential the, the policy paper is, you know, in terms of hearts and minds, um, as, uh, hospitals, uh, in certain states that have COPA laws, um, continue to explore whether they are shielded from federal antitrust liability for those transactions.</p> <cite>Speaker 2:</cite> <time>16:27</time> <p>So this has nothing to do with the COA policy paper, but I, I, I'm maybe dating myself, but whenever I hear copa, I always think of Barry Manilow. I don't know if that's just me<laugh> in any event, um,<laugh>, um, in any event, I previewed this a little bit earlier. Uh, PBMs, um, pharmacy benefits managers, uh, for those who are unfamiliar are now under the microscope, and, uh, Alexis is gonna tell us all about that.</p> <cite>Speaker 3:</cite> <time>16:58</time> <p>Yeah. Um, obviously, you know, the high and rising cost of pharma pricing has been, uh, the subject of a lot of attention across the country, including the Washington and the FCC is definitely putting a spotlight on, on PBMs or did in 2022. Um, so a couple key developments here. Uh, so in June, the FTC announced it was launching, uh, what it calls a six B study of PBMs. It's basically a study that the agency conducts by issuing subpoenas effectively to, uh, industry participants. So in this case, it's sent these special order subpoenas, basically to six PBMs, um, and ask them to submit, uh, an, you know, information about a wide range of topics. I think there were a total of 30, 38 requests. And the goal, uh, the FTCs goal is to study the effect that vertically integrated PBMs in particular have on access to prescription drugs and drug pricing. The F T C said it wanted to look into certain practices that had, quote, unquote drawn scrutiny, and it pointed to fees and, uh, clawback charges to unaffiliated pharmacies, steering patients to P B M owned pharmacies, uh, potentially unfair audits of independent pharmacies and other practices that it thinks, um, results in higher prescription drug prices. Um, also that same month, the FTC unanimously, which is pretty rare these days at the FTC unanimously issued a policy statement on rebates and fees in exchange for excluding lower drug cost drug products. So basically what this statement was, is a warning to drug manufacturers, PBMs, and other so-called middlemen as agency described them, uh, that the agency was gonna go after practices that the agency believes harms competition and patients. Um, so for example, the agency said that it was concerned that drug companies were using rebates and fees to put higher cost drugs on formularies and keeping lower cost drugs off formularies, resulting in higher prices for consumers. The FCC said that some of these practices could not just be unreasonable restraints of trade and ization, pretty standard antitrust claims, but also could be commercial bribery under the Robinson Patman Act. And, uh, the Robinson Patman Act is, uh, going, uh, uh, a revitalization, I would say at the FTC these days. But, um, we won't get into weeds on that, but, uh, certainly a lot going on with PBMs in 2022 and, and not likely to end anytime soon, Pete.</p> <cite>Speaker 2:</cite> <time>19:35</time> <p>Yeah. And that's the, uh, the concept of a rebate wall, if I'm not, if I'm not mistaken. Is that right, Alexis? That's</p> <cite>Speaker 3:</cite> <time>19:42</time> <p>Right. The term, yeah, another term.</p> <cite>Speaker 2:</cite> <time>19:44</time> <p>Yeah. It's a, it's, it's a fascinating area and certainly one, uh, to, to keep an eye on. Um, shifting gears back to the criminal realm, this is just a coincidence, John, I swear. Um, uh, we're gonna talk a little bit about no poach.</p> <cite>Speaker 4:</cite> <time>20:02</time> <p>Yeah. So, um, coming in at number four, the, the, what's been going on in 22 in the, in the, uh, department of Justices ongoing, um, cases, uh, some which have, have been resolved in the no poach arena. So I'm gonna cover two very quickly. Um, the first is, um, in US versus he slash vda, uh, the doj, the U S D OJ got its first guilty plea, um, ever, I believe in a no poach, uh, wage fix case. This involved nurse staffing in Nevada. Um, the indictment came down in May of 2021, and there was a guilty plea, um, on October 27th of, of last year, 2022. Uh, according to the plea agreement that they entered into with the government, um, V D a, uh, through one of its employees had participated, uh, in a conspiracy with another contract, healthcare staffing firm to suppress and eliminate competition by agreeing to allocate n nurses and fix the wages of those nurses. Um, at the, at the same hearing during which VDA pleaded guilty, uh, the judge, uh, the US District Court judge sentenced them to pay a criminal fine of 62,000 in restitution of 72,000 to the victim nurses. Um, in contrast, uh, in us, uh, versus Genal, uh, that was, uh, do J'S first ever criminal wage fixing case. They charged, uh, near a genal, a former owner of, uh, Texas Healthcare Staffing Company, as well as another, uh, employee there. And, uh, in April of, uh, 2022, uh, April 14th, to be specific, um, it was, they were found not guilty, uh, after a six day trial. Uh, however, I would note that, uh, genal was convicted not on, on antitrust, uh, claims, but of obstructing the FTCs investigation's investigation of, uh, of the allegations. Um, and, and so it wasn't a completely non-guilty, not guilty, uh, verdict. Um, so those are, those are some developments. I know that there are others, Pete.</p> <cite>Speaker 2:</cite> <time>22:07</time> <p>Yeah. And, uh, just to talk very briefly, I'm gonna, I'm gonna get John A. Little bit of a break here, uh, just to talk briefly about DaVita. Uh, so couple things have been happening with DaVita. So first in US versus theory, T H I R Y. Um, back in April, a jury in Denver, Colorado acquitted a dialysis provider, DaVita, and its former c e o Kent Theory of charges that they conspired with cons competitors, not to hire each other's employees. DOJ had alleged that DaVita and its competitors, including surgical care associates, suppressed competition by agreeing not to solicit each other's senior level employees, and requiring those employees who sought work, uh, to notify their current employers that they were job hunting. Uh, it is worth noting that despite the, uh, not guilty verdict, that this case did survive a motion to dismiss. So it was not without some risk. Um, and indeed, in September, in, in Ray Outpatient Medical Center employee antitrust litigation, a judge in the US District Court for the Northern District of Illinois denied DaVita's motion to dismiss plaintiff employee claims on essentially the same facts that d OJ had alleged in the, in the criminal case. And, uh, Kim Theory is one of the main defendants in that case. So he's not completely out of the woods, uh, just yet. So there's lots going on in this space. Um, turning back to mergers, uh, I'm gonna hand it off to Alexis to talk about Illumina Grail.</p> <cite>Speaker 3:</cite> <time>23:54</time> <p>Thanks, Pete. And this is the first of a, a couple vertical merger cases we're gonna be talking about. Um, and so an Illumina Grail, the FTC suffered a pretty, I'd say a pretty sunny defeat, uh, when its own in-house administrative law Judge rejected the agency's, uh, attempt to block Illumina's acquisition of grail. Uh, for, for folks who may not be familiar, Illumina is the largest, I believe, supplier of next generation, D N A sequencing platforms or NGS platforms for short and Grail at the time was developing a, if not a, the leading candidate or multi canncer early detection tests or M C E D tests. Um, I think since then, it's now launched those tests. Um, so this was a vertical combination, as I said. And so the agency sued to challenge this deal in 2021, alleging that Illumina had the ability and incentive either to withhold its own NGS platforms entirely from competing M C E D M C E D test developers that competed with GRAIL in order to disadvantage m relative to Grail, or that Illumina could, you know, raise the prices of its NG s platforms to those competitors, deny technical assistance on its platforms to those, uh, test rivals or hurt grails rivals in other ways. Uh, just before the complaint was filed, Illumina offered what it called its open offer to, uh, rival, uh, M C E D test developers through a so-called, uh, tw, uh, irrevocable 12 year supply commitment, uh, on Illumina's NGS platforms and related products. And, you know, specifically Illumina said it was going to promise to give access to the same services and supports to those rivals that Grail had access to. It wasn't gonna discontinue any products, uh, that GRAIL's rivals, uh, bought from Illumina during the term of those 12 years. Uh, it offered these, uh, companies either grandfathered pricing that they were paying for Illumina's products or to pay prices that were no higher than Illumina was charging grail. Uh, but the F T C, uh, reject that offer and went ahead of the litigation. Um, in September, though, the ALJ ruled against, uh, against complaint counsel, basically F T C staff that was litigating the case, um, finding that the, the staff had failed to prove that the deal would hurt competition for M C E D tests. Uh, the ALJ acknowledge ALJ acknowledged that Illumina Lumina's market position gave it the ability to harm grill's competitors. Um, but that the open offer, um, basically took away that ability to harm those rivals. And in any case, Illumina didn't have the incentive to foreclose those rivals or harm them in other ways, because it would lose, um, as many or more sales of its NGS platforms to those rivals without kind of recouping those lost sales to higher revenues from greater Grail, uh, M C E D test revenue. Um, so that loss has been appealed by the F T C staff to the full commission, which is now, uh, consists of four members. Uh, and we're waiting for that decision. Um, there's also litigation happening across, uh, the pond because the European Commission, uh, uh, ordered Illumina to unwind, uh, the acquisition of braille. So, uh, a lot going on in this case, um, but a big laws for the FTC in its home court.</p> <cite>Speaker 2:</cite> <time>27:23</time> <p>Yeah. And we are seeing that more and more, not just with the ftc, but the DO OJ where parties have found some receptive audiences with judges, um, when they offer remedies that maybe the FTC or DOJ staff or the OR leadership are not willing to accept. So, uh, that's a great example of, of that strategy really paying off, at least, at least on this side of the pond. Um, so turning back to John, uh, we're gonna talk about United change.</p> <cite>Speaker 4:</cite> <time>27:55</time> <p>Yeah. Speaking of appeals, right, um, uh, the doj uh, brought a, uh, a case to block, uh, United Health Groups, uh, 13 billion acquisition of change, uh, back in February alleging, uh, couple different, uh, sources of harm, including horizontal overlap and, and first pass claims editing. But, but really, the heart of that case was, and is the, the so-called vertical concerns for the, um, the electronic data interchange clearing houses. Um, DOJ alleged that the, the transaction would give United, uh, which owns the largest health insurer in the us, access to a vast amount of its rivals, uh, rival health insurers, uh, competitively sensitive information now would cause, uh, a, a lot of competitive harm. Uh, DOJ was not successful in at the D D C, uh, the court denied, uh, the, the, sorry, the federal court and the District of Columbia. Uh, the court denied the injunction they had. The court agreed, um, with the parties that their proposed dives chair for the claims, uh, uh, space and the firewalls that they were putting in place, um, uh, as well as the, the, the<inaudible> more broadly would resolve the, both the horizontal and the vertical concerns, and that there wasn't evidence, um, that, uh, United would be able to withhold, uh, integrated platforms, uh, and, uh, that the, uh, United had incentives to protect its con its customers data, and that those incentives would outweigh their incentives to, to misuse the data. So, um, uh, a case that DOJ brought, and at least for now, uh, was not successful in bringing the parties close the transaction in early October. It is on appeal, uh, and so we'll be, we'll be talking about it shortly as we, as we look forward to this year.</p> <cite>Speaker 2:</cite> <time>29:46</time> <p>Okay. So we've reached number one. I'm not gonna steal Alexis's thunder. Alexis, do you want to take it away?</p> <cite>Speaker 3:</cite> <time>29:54</time> <p>Sure. Uh, what we have is our number one development, uh, as the biggest development, although perhaps not surprising, is, uh, the ftc, uh, is back on a wind streak and hospital merger challenges. Um, it forced three hospital mergers to be abandoned, uh, this past year. Um, you know, this comes after the FTC losses first case in a couple decades, two years ago. Um, but I think last year shows it's, uh, back, um, on a wind streak, uh, and, and is not backing down from, from challenging provider merger. So, um, the first case, uh, the FTC challenge was in February, uh, seeking a block, uh, and ultimately blocking the acquisition or combination of lifespan and care in New England. Uh, the FTC said this deal would combine the two largest healthcare providers in the state of Rhode Island and harm competition in two markets. First was inpatient general acute care hospital services. That's a, a very traditional, uh, product market. The FTC alleges in hospital merger challenges, and the second was inpatient behavioral health services. And as far as I know, that's the first time, um, outside of settlement context, the FTC is alleged that in a hospital merger complaint. Um, I'd say another interesting part of this case is that in a concurring statement announcing the complaint, the two Democratic commissioners said they would've also alleged ARM in a labor market. They didn't specify which one, but, uh, there was analysis, um, presentation by the Rhode Island Attorney General raising concerns about competition to employee registered nurses. Um, so that's probably the market the FTC was also concerned about. Um, but that allegation, as I said, didn't make it into the complaint. Uh, there were four commissioners at the time, and the two Republicans were opposed to that allegation. So that ultimately didn't make its way into the complaint, uh, but I think shows FTC interest and labor market issues and mergers and, and otherwise. Um, so that deal was abandoned. In the second case, the FTC challenged, uh, HCAs proposed acquisition of Steward Healthcare's hospitals in Utah. The FTC said that transaction were har harm competition in inpatient general acute care hospital services in three geographic areas around the Salt Lake City area. And I think, I guess one thing I'd point to is, what was interesting about this case is that the FC pointed, uh, uh, evidence or alleged, there was evidence that the parties provided price concessions to payers in order to exclude the other party from payer networks, and that the parties were particularly close competitors to one another for patients in narrow networks, where the largest provider in the area Intermountain, was less competitive with the merging parties, uh, for those narrow networks, that transaction was abandoned. And in the third complaint, the FTC stew to stop the merger of, uh, R W J Barnabas and St. Peter's Healthcare in New Jersey there, the F T C alleged that, uh, the merger of R W J, which was one of the largest healthcare systems in the state of New Jersey and St. Peters, who had its hospital just a mile from R W J's Flagship Hospital, that that deal would harm, uh, general acute care competition in Middlesex County, New Jersey. Um, saying that the parties had about a 50% share, and they'd be, uh, the only, uh, there would only be two other remaining competitors in that county. So that deal was also abandoned. And I guess I should mention that besides these three deal abandonments, the T c also got a favorable decision out of the third circuit in 2022, upholding a district court decision blocking the Hackensack Meridian Englewood healthcare. So, uh, 2022 was, uh, a big year for F t FTC Hospital merger enforcement. And, uh, I'd say that is also expected to continue. So that's, uh, number one. As far as, uh, we're concerned, at least stop, I'll speak for myself.</p> <cite>Speaker 2:</cite> <time>33:49</time> <p>Well, I think it's a worthy number one for sure. Uh, no countdown would, uh, would be complete without a hospital merger challenges because the FTC has been, uh, so active in that area. And of course, with back to back wins in New Jersey, uh, we, you know, we just had to put it at number one, right? Yes. Um, okay. So we've looked backwards, and now we're gonna break out the crystal ball for 2023 to talk about the 10 things to watch for in the coming year. And I'm gonna turn it back to Alexis to talk about the fifth FTC Commissioner.</p> <cite>Speaker 3:</cite> <time>34:28</time> <p>Yeah. So right now, uh, and since October when commissioner, Republican commissioner Noah Phillips stepped down, the FTCs been operating with four out of the five seats filled, three Democrats, one Republican. So we're watching out, um, to see, uh, whether and when a fifth commissioner may be nominated and who it will be. I haven't been hearing many names being floated. Maybe you guys have, but, um, we could potentially be waiting a while, though. Uh, the, the Democratic president doesn't have an obvious motivation to fill, uh, a Republican seat that quickly at the F T C, uh, since that seat has to be filled by a Republican, or at least someone who is not a Democrat, um, in any case, I'm not sure that open seat really matters all that much, because with three Democratic votes, the majority can pretty much approve any enforcement action or policy, uh, decision it wants without, uh, Republican votes, whether it's one or two. Uh, but still, uh, important seat to Phil and we'll be watching, uh, to see, um, who may join, uh, commissioner Wilson as, uh, a second non Democrat on the F T C in 2023.</p> <cite>Speaker 2:</cite> <time>35:38</time> <p>Yeah, that is a, it's an interesting conundrum if, uh, for, for the president, because there really isn't much incentive. But on the other hand, not much downside either, I guess<laugh> Yeah. Uh, for, to add a Republican, uh, because they're gonna be outvoted, um, pretty much no matter what. Uh, but yeah, it's gonna be an interesting process to, to watch for in 2023. So, turning back to John, we're gonna talk about the future of United change, John.</p> <cite>Speaker 4:</cite> <time>36:08</time> <p>Yeah, thanks, Pete. This is going to be really short as I covered most of the substance, um, when we were looking back at the case in 2022. But one of the developments in, in, in our view, I guess the ninth most important healthcare antitrust development or, or, or thing to look for, uh, in 2023, is what happens, um, at the DC Circuit with respect to the Department of Justice's challenge to that transaction. As I mentioned just moments ago, the deal did close, uh, uh, in October. Uh, and so, uh, we are, uh, anxiously awaiting, uh, that decision, and I'm sure there'll be a lot of great content, uh, from the H L A, uh, once that decision, uh, comes out.</p> <cite>Speaker 2:</cite> <time>36:48</time> <p>Yes, for sure. Regardless of which way it goes. Right. Um, so we're up to number eight, and we're going back to cos uh, so Alexis, do you wanna talk about Sunni?</p> <cite>Speaker 3:</cite> <time>37:02</time> <p>Yeah. So, uh, as John mentioned, the FFC has been making a push, uh, against cop's. Um, and a couple months after it issued, um, the policy paper, uh, maybe it doesn't even that long, but after it issued the policy paper, John mentioned in 2022, uh, the staff filed a public comment opposing or asking the New York Department of Health to not grant a COPA to a combination of SUNY Upstate Medical Center and Kraus Health System, which are, uh, located as far as I can tell, basically right across the street or adjacent to each other, um, in, in upstate New York. Uh, and the FTC CO basically says that the proposed merger has a quote, substantial risk of serious competitive harm and consumer harm in the form of higher healthcare costs, lower quality, reduced innovation, reduced access to care, and depressed wages for hospital employees. Um, picking up on that last point, I think one of the things that's interesting about this is that the IC isn't just alleging harm to inpatient general acute care competition, but for the first harm, as far as I can tell, um, you know, alleging harm in various labor markets, um, it put forward alleged hospi or employment market shares for registered nurses, respiratory therapists, and hospital employees overall in, in what it's called the commuting zone, how far, you know, employees are, would be willing to compute in the com commute in the area. So I think that's a really interesting element beyond just the overall element that the FTC has been unsuccessful at stopping any of the recent COPA approvals in recent years. So we'll see if they have any different outcome, um, in, in New York, uh, potentially in 2023.</p> <cite>Speaker 2:</cite> <time>38:54</time> <p>Great. So now we're up to number seven. And John, I believe you're gonna talk about big healthcare deals.</p> <cite>Speaker 4:</cite> <time>39:03</time> <p>Yeah, that's, that's the best phrase we could come up with, right?<laugh>. Um, last couple of years we've seen a lot of, or at least a number of, um, large transactions that are interesting in the healthcare space because they combine different types of companies. So some, some, uh, tech, uh, provider deals. We've seen, certainly pharmacy provider deals, all sorts of different transactions that not just have high dollar figures in terms of the enterprise value of the transactions, but are also interesting to those of us who are practitioners and, and I would imagine also to those who follow the industry. And so, in 2023, what we're, um, really gonna be interested in seeing, and, and I know you all are, is what's next in terms of large transactions. There are, uh, a number of startups that have been, uh, talked about as acquisition targets by larger players. Uh, how do the agencies grapple with those antitrust issues? And, um, what is the reaction as the market continues to evolve in healthcare? It's one of the most dynamic, uh, industries I think we would agree in the world, certainly one of the most in the United States. It's also a sixth of our economy. And so when we see large transactions in the ecosystem, um, they certainly get our attention more than just from an antitrust perspective. But again, um, from those, for those of us who, who followed the industry closely.</p> <cite>Speaker 2:</cite> <time>40:25</time> <p>So I'm gonna give the guys a break, uh, and take one, uh, at number six. Speaking of big deals, I'm gonna talk a little bit about Amazon One Medical. So in July of 2022, Amazon announced that it was buying one medical for 3.9 billion. For those who aren't familiar, uh, one medical focuses on primary care, telemedicine and in-office care with locations at various major cities like Atlanta, Boston, Chicago, Phoenix, la, and New York, as customers can book same or next day appointments with providers in their area through its app. Now, Amazon is not exactly known for healthcare. Uh, it has a very small presence in healthcare, uh, and there doesn't appear to be any obvious meaningful overlap between IT and one Medical. Nevertheless, two months after the deal was announced, public reports stated that Amazon and One Medical had received second requests from the F T C. Uh, for those who are not familiar with the second request, it's a very large invasive subpoena, essentially asking for documents and data, uh, and written responses, uh, and takes months and months and months to comply with. Usually, uh, traditionally, the agencies, the DOJ and the FTC probably wouldn't have seen a problem with this type of deal because there are no obvious competitive overlaps. Uh, so one might ask, well, why did the FTC issue a second request? Uh, well, this, the answer may be as simple as it's Amazon. Um, because the FTCs current chair, Lena Khan, has argued that antitrust enforcement and specifically with respect to Amazon, uh, requires a much more aggressive approach. It will be very interesting to see if the FTC tries to find a perhaps less traditional basis for challenging this deal. Uh, for those who aren't familiar, uh, Terracon authored a very influential note in the Yale Law Journal titled Amazon's Antitrust Paradox, where she argued that the current framework in antitrust, and specifically it's focus on consumer welfare and short-term price effects, is really not well equipped to deal with the architecture of market power in a modern economy, particularly with respect to Amazon. Uh, she has also called for changing the FTCs overall strategic approach, uh, to look more holistically and harm from transactions, including harm to workers, as we just talked about, uh, as well as independent businesses and of course, consumers. So, uh, chair Con is, is really looking for FTC enforcement, uh, to focus not just on the deal at hand, but the underlying causes and structural incentives that could lead to unlawful conduct in the future. Um, and it wouldn't surprise anyone probably to, to know that Amazon's announcement of the deal also got the attention of Capitol Hill, uh, specifically from Senator Klobuchar. So, uh, a lot of attention on this deal, even though, uh, it doesn't fit the traditional mold of a deal that the agencies would've historically been all that concerned about. So, bottom line, uh, perhaps, uh, despite all of the pressure to do something about Amazon, it's still an open question as to whether the F T C will challenge it, because ultimately the FTC does have to convince, convince a judge, uh, to block a deal, can't do it on its own. So this is definitely one to watch for in, in 2023. So, next up, we have more no poach, uh, this time up in, in Maine and, and elsewhere, John.</p> <cite>Speaker 4:</cite> <time>44:33</time> <p>Yeah, thanks. So, um, some things to keep an eye on in the no poach space, certainly. Uh, and, and, and also there's a, a class action in Illinois, but in Maine, um, there was a, an indictment, uh, early in 22, uh, in the home healthcare agency space, um, that alleged, uh, that these agencies were participating in conspiracy to suppress wages. Uh, so that was, uh, uh, an indictment of a few individuals in the district court of Maine. We'll see what happens, um, in, in 2023. Um, and then also, um, there was a, a, a class action, uh, in Illinois, um, sort of unrelatedly, um, just so we thought we'd loop in, uh, or, or include in this, um, actually involved, uh, involving advocate, uh, Aurora that was filed on, on Tuesday, brought by Euro ure pharmaceutical, uh, pharmacy, um, that had to do with, um, the way, uh, that the, the hospital system allegedly uses, its, its market power to quote, take huge sums of money from the pockets of Wisconsin employers. So those are cases, um, and, and actions we're gonna be following, uh, there's a lot going on, lot to follow, but that's what came in, I think, with, uh, under the consensus, our consensus for, for number five.</p> <cite>Speaker 2:</cite> <time>45:54</time> <p>Okay. Yeah, no poach. I think, uh, it's safe to say that that's gonna be a hot area going forward for both, uh, the FTC and DOJ and, and we'll probably seeing more and more of this, uh, private litigation as well. Um, so definitely an area to watch, uh, at number four, the FTCs use of its Section five authority. Alexis.</p> <cite>Speaker 3:</cite> <time>46:19</time> <p>Yeah, thanks, Pete. Um, we didn't touch on it as a key de, you know, healthcare development in 2022, since it's not specific to healthcare may, maybe we could have, uh, but certainly one to watch this year. So last November for context, uh, the FTC issued a new policy statement on the scope of its authority under section five of the FTC Act, which prohibits, quote unquote, unfair methods of competition. Um, I think in a nutshell, it's safe to say that the policy statement reflects a pretty expansive view of the agency's authority under section five to go, uh, after conduct well beyond the bounds of what, um, is traditionally pursued under section one in section two of the Sherman Acts or strengths of trade and monopolization claims. I think everyone agrees that there's some scope for section five to go beyond those statutes, but how far is, has always been a question. And I think this policy statement says quite a bit farther. Um, so we have it as a key development in 2023, uh, one to watch, because the policy statement identifies a bunch of practices that it says could violate section five, and several of them, uh, appear to be relevant to healthcare. So, you know, the types of conduct that could violate Section five, according the statement include actual or de facto loyalty rebates, tying, bundling, exclusive dealing arrangements, a series of mergers and acquisitions that collectively harmed competition. Even if individually, none of those transactions would violate the antitrust laws, acquisitions of mason and potential competitors, uh, quote unquote discriminatory refusals to deal that tend to create or maintain market power, uh, whatever that means, and other practices. So, um, certainly wide scope of agencies trying to carve out for things that could violate section five. Um, we're now seeing the first, uh, indications of that in the labor, uh, employment context, which will, I think come up, uh, in one of our, uh, later things to watch in 2023. But let me leave it there. Beep.</p> <cite>Speaker 2:</cite> <time>48:30</time> <p>Okay, that's a good teaser, uh, for, for something coming up. Um, so at number three, we have, uh, a topic that I think I probably would've expected to be in the top 10 developments of 2022. Uh, but now we're, we're looking at it in 2023. So, uh, I'm gonna hand it off to John to talk about that one.</p> <cite>Speaker 4:</cite> <time>48:50</time> <p>Yeah, these are the anxiously awaited new horizontal merger guidelines, uh, to be put forth by the agencies. So the last version of the, uh, horizontal merger guidelines, which for those of our listeners who don't know, are, um, the, uh, the, the, the, the guidelines pursuant to which the FTC and doj, uh, enforce, uh, transactions under their authority of section seven of the Clayton Act. Uh, and they were last updated and revised, uh, in 2010. So it's been quite some time. They do not, uh, they're not law, they don't have the force of law. It's not a statute, but really what it is, is telling, uh, practitioners and, um, and firms en engaging in transactions, how, again, how the agencies view and interpret and enforce the antitrust laws. And so, uh, there was a lot of noise, um, a around, uh, the, the new version of these particularly, um, when the new, uh, leadership was put in place, uh, at, at both agencies. There's a public comment, uh, period, uh, and, and I believe some, even some, uh, town halls and other events that were held, uh, back in the earlier part of 2022. Thus, Pete, your comment with respect to, uh, anticipating these having been issued prior to, prior to 2023. Uh, so we are, we're really looking forward to, to seeing what gets put forth. Um, lot of things that could potentially be in them. We could speculate endlessly, but you know, some of them have actually been covered on this podcast. You know, like cross market issues, uh, or, or, you know, uh, mergers where the, the firms are not in the same geographic market. Uh, vertical transactions, market definition, uh, presumptions or bright lines about the types of mergers that should be considered illegal according to clear rules, as opposed to, uh, the, the more fact by, uh, fact, uh, or, or case specific or fact specific analysis largely employed now. So we're really looking forward to these. I'm sure when they come out, um, there will be a lot of coverage a, across the industry and, and certainly, um, will affect, uh, the healthcare industry and, and the transactions that, that folks may be contemplating.</p> <cite>Speaker 2:</cite> <time>51:02</time> <p>Yeah, absolutely. And I think, uh, it's safe to expect that if, if the thresholds that were in the previous guidelines are lowered, then one direct effect could be the, uh, F T C staff are more able to pursue challenges of cases that they might not have otherwise to, to block deals. So, yeah, it's gonna be fascinating. Uh, it could have a very significant impact on how the agencies review mergers. Uh, so that is definitely one to keep an eye on for 2023. Uh, now we're up to number two, and I'm gonna hand it off to Alexis again.</p> <cite>Speaker 3:</cite> <time>51:44</time> <p>Yeah, we, um, we put this in two, you know, we could probably have flipped it with the murder guidelines revisions, but we'll, we'll slot it here. Uh, which is the decision, the FTC commission decision, uh, in the Illumina Rail, uh, challenge, as I mentioned, the FTC staff suffered a pretty surprising defeat in its administrative court in the case, uh, the commission, the four commissioners that are there now heard, uh, the appeal, we're now waiting for the decision. Um, I think based on, uh, recent history, I think there's a lot of folks who expect that the FTC will reverse the ALJs decision. Um, that's suggested to commission of some criticism about how successful it is in its own administrative court. But, um, I still think it'll be interesting to see, uh, if that is the case, what the commission's rationale is for or returning the decision. Um, and whether the parties appeal that to a, a circuit court. Uh, I think the decision's gonna be interesting as well, because it, it might be released around the time, or, you know, just before or after these new merger guidelines come out, at least in draft form. So, how the F FTC decides this case might give us some insight into how the agency is thinking about vertical mergers, um, how the commission deals with the existing vertical merger, a recent vertical merger case law that hasn't gone the agency's way. They've, they've lost the challenges they've recently filed against vertical mergers in court. And also how the FTC treats, um, behavioral remedies to solve, uh, vertical merger concerns, which they've, um, shown, uh, hesitance, if not, you know, um, uh, reticence to, to adopt. So, um, uh, certainly a big decision decision probably could have been lumped in with John's big healthcare merger transactions as well, but certainly, um, a, a key decision because, uh, of the various issues, including the vertical nature of the case and the context of these new guidelines coming out.</p> <cite>Speaker 2:</cite> <time>53:42</time> <p>Okay, so we're up to number one. Everyone is on the edge of their seats. So, uh, without further ado, John, what's number one?</p> <cite>Speaker 4:</cite> <time>53:52</time> <p>It's, it's my pleasure to be, uh, talking about the number one most anticipated healthcare antitrust development 2020.</p> <cite>Speaker 3:</cite> <time>53:59</time> <p>Is it criminal</p> <cite>Speaker 4:</cite> <time>54:00</time> <p><laugh>? No, unlike me, uh, it's, uh, it's something, it's something I think that actually, uh, we, we'd all agreed would be a major development. The Federal Trade Commission's, uh, rule making, uh, on in particular non-competes, um, as well as some other things like exclusive contracts. The ftc, uh, issue proposed, uh, uh, notice, uh, or sorry, a notice of proposed rulemaking under, uh, 16 C F R part nine 10, that would essentially, uh, be a rule, uh, under, its under its section five authority, rulemaking authority to ban, uh, non-compete, uh, provisions or non-compete clauses, uh, in the employment context. So, not necessarily, or not in the deal context, but specifically according to the FTCs definition, a contractual term between an employer and a worker that blocks the worker from working for a competing employer or starting a competing business, typically within a geographic area. And a period of time after the worker's employment ads, we're looking at the proposed rule, um, it will be subject to a public comment, uh, period, uh, that, uh, I believe is due 60 days after the federal register, uh, publishes the proposed rule. Proposed rule is on ftc.gov encourag folks to look at it. Um, this is something that has a lot of implications, uh, certainly too many to discuss on, on this relatively abbreviated high level podcast. But just looking at the commission or the FTC statement alone that accompanied this, you know, they estimate that this rule, uh, assuming this is actually promulgated in an upheld is enforceable, uh, would increase American workers earnings. And I'm quoting between 250,000,000,290 6 billion, uh, per year. So, um, certainly a, a massive, uh, potential impact on, uh, a number of industries, of course, on the healthcare industries, you know, non-compete clauses, um, are, are, uh, relatively common in the healthcare industry in a variety of contexts. And so, uh, again, lot to think about here, uh, including, um, without opining one way or the other, but just pointing out whether, um, this rule actually, uh, is promulgated in the way it was originally proposed, proposed. So we'll see what happens during the public comment period. And then, of course, um, what would expect if promulgated and enforced, um, there will be challenges, uh, to, to the rule, uh, constitutional challenges, uh, et cetera, administrative process challenges. And so I imagine this is something we're gonna be talking about, uh, in the anti, in the antitrust world, and certainly in the, in the labor and employment arenas as well, uh, for quite some time. And, uh, stay tuned. Uh, we're, we're, we're gonna be, uh, analyzing it and, and talking about it. And it's, uh, an interesting development. And I guess the last thing I would say, it's not, it's not, it's an interesting development. It's something we had to look forward to in 2023. Um, it's not a surprising development, uh, in my view. So a little bit of editorializing, this is something that was in, um, president Biden's, uh, uh, July, 2021, executive order on competition, where the executive branch outlined what they viewed to be their enforcement priorities in US antitrust enforcement, non-competes, was, was front and center in that, uh, executive order. And this is something that, um, everyone pretty much knows, uh, the FTC has been working through both, both on, uh, in terms of bringing cases and enforcement actions, but also more broadly in terms of rulemaking. And so, uh, looking forward to seeing how this development develops and, uh, appreciate being given the opportunity to talk about number one in 2023. I'm not sure I've had that honor before when we've done this podcast the next year of number one. Uh, and thanks so much for, uh, Pete, for, for doing this with us. Alexis, always, always a great time, uh, doing this. And, and thanks to h l a for putting this on. This has been a lot of fun</p> <cite>Speaker 3:</cite> <time>58:02</time> <p>For sure. Echo those sentiments for sure.</p> <cite>Speaker 2:</cite> <time>58:06</time> <p>Okay, well, quite a list. Uh, so that's all we have for today. Uh, I, I do want to thank the A H L A, and of course, uh, my fellow, uh, panelists or podcasters, uh, Alexis and John for their excellent work. And of course, uh, infinite patience with me as moderator today. Um, and to our listeners, thank you for joining and I hope everyone has a wonderful new year. Lots to look forward to in 2023. And as John said, stay tuned.</p> <cite>Speaker 1:</cite> <time>58:49</time> <p>Thank you for listening. If you enjoy this episode, be sure to subscribe to a H L A speaking of health law, wherever you get your podcasts. To learn more about a H L A and the educational resources available to the health law community, visit American health law.org.</p> </div> </div> </div> </div> </div> </div> <div class="hidden xl:block"> <aside class="pt-10 xl:pt-2 px-0 xl:px-8 border-0 xl:border-l border-gray-200" role="complementary"> <div> <h3 class="text-xl font-bold">Follow</h3> <div class="py-2"> <a class="flex items-center gap-2 py-2" target="_blank" href="https://podcasts.apple.com/us/podcast/ahlas-speaking-of-health-law/id1340502198?mt=2&uo=4"> <svg width="34" height="34" viewBox="0 0 34 34" xmlns="http://www.w3.org/2000/svg" class="w-7 h-7"> <g> <path d="M31.4065 28.002C31.1149 28.7427 30.442 29.7857 29.4878 30.5203C28.9368 30.9446 28.2791 31.3502 27.3756 31.6179C26.4126 31.9033 25.2263 31.9998 23.7499 31.9998H10.25C8.7737 31.9998 7.58744 31.9033 6.62425 31.6179C5.72079 31.3502 5.06316 30.9446 4.51212 30.5203C3.55799 29.7856 2.88498 28.7427 2.59337 28.002C2.00596 26.5096 2 24.8163 2 23.7499V10.2499C2 9.18347 2.00596 7.49016 2.59337 5.99774C2.88498 5.25702 3.55787 4.21407 4.51212 3.47942C5.06304 3.05511 5.72079 2.64952 6.62425 2.38187C7.58733 2.09645 8.77358 2 10.25 2H23.75C25.2263 2 26.4126 2.09645 27.3757 2.38187C28.2792 2.64952 28.9368 3.05523 29.4879 3.47942C30.442 4.21419 31.115 5.25702 31.4066 5.99774C31.994 7.49016 32 9.18347 32 10.2499V23.7499C32 24.8162 31.9939 26.5095 31.4065 28.002Z" fill="url(#paint0_linear_4_2_apple_b310940e07)" /> <g> <path d="M19.1757 19.2433C18.7255 18.7683 17.9349 18.4638 17.0015 18.4638C16.068 18.4638 15.2773 18.7683 14.8271 19.2433C14.5922 19.4911 14.468 19.7452 14.4289 20.1072C14.3531 20.8081 14.3956 21.4116 14.4778 22.3764C14.556 23.2959 14.7045 24.5219 14.8984 25.7707C15.0363 26.6593 15.1484 27.139 15.2505 27.4825C15.4159 28.0391 16.0343 28.5259 17.0015 28.5259C17.9685 28.5259 18.5869 28.039 18.7524 27.4825C18.8544 27.139 18.9665 26.6593 19.1044 25.7707C19.2983 24.5219 19.4468 23.2959 19.525 22.3764C19.6072 21.4114 19.6497 20.8079 19.5739 20.1072C19.5348 19.7453 19.4106 19.4911 19.1757 19.2433ZM14.5486 15.0141C14.5486 16.37 15.6478 17.4693 17.0037 17.4693C18.3598 17.4693 19.459 16.37 19.459 15.0141C19.459 13.6581 18.3598 12.5589 17.0037 12.5589C15.6478 12.5589 14.5486 13.6581 14.5486 15.0141ZM16.9733 5.32489C11.2313 5.34131 6.52617 9.99966 6.45511 15.7414C6.39741 20.3926 9.36651 24.3712 13.5124 25.8296C13.6131 25.865 13.7152 25.7814 13.6994 25.6759C13.645 25.3148 13.5938 24.9519 13.5467 24.595C13.53 24.4689 13.4496 24.3602 13.3331 24.3092C10.0562 22.8776 7.76798 19.5912 7.8047 15.7843C7.85287 10.7884 11.9324 6.71558 16.9283 6.67516C22.0356 6.63391 26.2037 10.7766 26.2037 15.8745C26.2037 19.6433 23.9255 22.8894 20.6741 24.3096C20.5576 24.3605 20.4777 24.4696 20.4612 24.5956C20.4141 24.9523 20.3628 25.3151 20.3086 25.6759C20.2926 25.7814 20.3948 25.865 20.4954 25.8297C24.6017 24.3853 27.5535 20.4685 27.5535 15.8747C27.5533 10.0472 22.8043 5.30828 16.9733 5.32489ZM16.7827 10.1648C20.0378 10.0388 22.726 12.6502 22.726 15.8778C22.726 17.5192 22.0306 19.0011 20.9191 20.0448C20.8248 20.1333 20.7741 20.2589 20.7814 20.388C20.8036 20.7806 20.7955 21.1622 20.7693 21.593C20.7623 21.7078 20.8911 21.7811 20.9861 21.7164C22.85 20.4426 24.076 18.3008 24.076 15.8778C24.076 11.8881 20.7528 8.65996 16.7292 8.81591C12.9899 8.96088 9.98992 12.0438 9.94199 15.7857C9.91051 18.2467 11.144 20.4269 13.0319 21.7167C13.1266 21.7814 13.255 21.7079 13.248 21.5933C13.2218 21.1622 13.2138 20.7806 13.2358 20.388C13.2431 20.259 13.1926 20.1334 13.0985 20.045C11.9523 18.9689 11.2484 17.4268 11.2932 15.7243C11.3722 12.7283 13.7877 10.2808 16.7827 10.1648Z" fill="white" /> </g> </g> <defs> <linearGradient id="paint0_linear_4_2_apple_b310940e07" x1="17" y1="2" x2="17" y2="31.9998" gradientUnits="userSpaceOnUse"> <stop stop-color="#F452FF" /> <stop offset="1" stop-color="#832BC1" /> </linearGradient> </defs> </svg> Apple Podcasts </a> <a class="flex items-center gap-2 py-2" target="_blank" href="https://open.spotify.com/show/6ybKuawm7eZSXsYS6zZhgh"> <svg width="34" height="34" viewBox="0 0 34 34" fill="none" xmlns="http://www.w3.org/2000/svg" class="w-7 h-7"> <g id="spotify"> <path id="spotify_2" d="M25.873 15.2978C21.0379 12.4264 13.0624 12.1623 8.44669 13.5632C7.70531 13.7882 6.92148 13.3698 6.69687 12.6286C6.47225 11.8869 6.89032 11.1036 7.63205 10.8782C12.9306 9.26992 21.7388 9.58052 27.3051 12.8847C27.9718 13.2806 28.1905 14.1416 27.7953 14.8072C27.3999 15.4739 26.5381 15.6937 25.873 15.2978ZM25.7147 19.5508C25.3754 20.1013 24.6558 20.2739 24.106 19.9359C20.075 17.4582 13.9281 16.7403 9.15904 18.1879C8.54054 18.3748 7.88748 18.0262 7.69958 17.4088C7.5133 16.7904 7.86204 16.1384 8.47946 15.9504C13.9274 14.2971 20.7001 15.0978 25.33 17.9431C25.8797 18.2816 26.0527 19.0017 25.7147 19.5508ZM23.8793 23.6353C23.6097 24.0774 23.0342 24.2158 22.5937 23.9464C19.0713 21.7936 14.6378 21.3075 9.41644 22.5C8.9133 22.6154 8.41177 22.3001 8.29695 21.797C8.18178 21.294 8.49595 20.7925 9.00017 20.6777C14.7141 19.3715 19.6153 19.9336 23.569 22.3496C24.0098 22.6188 24.1487 23.1947 23.8793 23.6353ZM17 2C8.71591 2 2 8.71572 2 16.9998C2 25.2848 8.71591 32 17 32C25.2845 32 32 25.2848 32 16.9998C32 8.71572 25.2845 2 17 2Z" fill="#1ED760" /> </g> </svg> Spotify </a> <a class="flex items-center gap-2 py-2" target="_blank" href="https://music.amazon.com/podcasts/9273aa38-0eef-477d-839e-50f09a5d70eb/AHLAs-Speaking-of-Health-Law"> <svg width="34" height="34" viewBox="0 0 34 34" fill="none" xmlns="http://www.w3.org/2000/svg" class="w-7 h-7"> <g id="amazon"> <g id="amazon_2"> <path id="Vector" fill-rule="evenodd" clip-rule="evenodd" d="M20.3674 14.5293C18.4624 15.3267 16.4194 15.742 14.3544 15.7519C11.592 15.7581 8.87501 15.0458 6.47157 13.684C6.27598 13.5704 6.13094 13.7711 6.29466 13.9191C8.46003 15.8545 11.2682 16.9152 14.1723 16.8954C16.3483 16.8954 18.8781 16.2141 20.6212 14.9333C20.9113 14.722 20.6629 14.4052 20.3674 14.5293Z" fill="#4524FB" /> <path id="Vector_2" fill-rule="evenodd" clip-rule="evenodd" d="M19.266 13.8085C19.1129 13.914 19.1393 14.0726 19.311 14.0437C19.8711 13.9752 21.1226 13.8272 21.3471 14.1096C21.5716 14.392 21.0988 15.5648 20.8875 16.0874C20.8241 16.246 20.9614 16.3094 21.1039 16.1903C22.0386 15.3981 22.2818 13.7792 22.0917 13.5496C21.9016 13.3199 20.2644 13.1111 19.266 13.8085Z" fill="#4524FB" /> <path id="Vector_3" fill-rule="evenodd" clip-rule="evenodd" d="M22.6807 11.8358C22.1437 11.5593 21.5434 11.4311 20.9405 11.4633L22.525 9.21845C22.6389 9.09539 22.7199 8.94558 22.7602 8.7826V8.2017C22.7602 8.10683 22.6832 8.02992 22.5887 8.02992C22.5869 8.02992 22.5851 8.02992 22.5833 8.02992H19.5224C19.4304 8.02699 19.3535 8.09914 19.3506 8.19071C19.3506 8.19437 19.3506 8.19803 19.3506 8.20133V8.88002C19.3491 8.97342 19.4235 9.05034 19.5169 9.0518C19.5194 9.0518 19.5224 9.0518 19.5249 9.0518H21.1094L19.2766 11.6662C19.1916 11.8058 19.1521 11.968 19.1631 12.131V12.8203C19.1631 12.9181 19.274 13.0317 19.3795 12.976C20.3922 12.4555 21.594 12.4555 22.6067 12.976C22.7202 13.0368 22.8312 12.9207 22.8312 12.8203V12.0995C22.8301 11.9915 22.7733 11.8915 22.6807 11.8358Z" fill="#4524FB" /> <path id="Vector_4" fill-rule="evenodd" clip-rule="evenodd" d="M25.3797 7.94308C24.0355 7.94308 23.2909 9.09169 23.2909 10.5681C23.2909 12.0445 24.0278 13.2089 25.3797 13.2089C26.6818 13.2089 27.4923 12.0603 27.4923 10.6128C27.5132 9.12099 26.758 7.94308 25.3797 7.94308ZM25.3797 12.2343C24.6508 12.2343 24.6615 10.9985 24.6615 10.4172C24.6615 9.83631 24.7036 8.91185 25.3878 8.91185C25.6764 8.89244 25.9353 9.08839 25.995 9.37152C26.1027 9.78137 26.1496 10.2051 26.135 10.6285C26.135 11.2362 26.1005 12.2343 25.3797 12.2343Z" fill="#4524FB" /> <path id="Vector_5" fill-rule="evenodd" clip-rule="evenodd" d="M15.17 10.2275C14.5562 10.4744 14.1602 11.0765 14.1771 11.738C14.1771 12.6991 14.7873 13.18 15.5689 13.18C16.1575 13.2126 16.7267 12.9624 17.1006 12.5064C17.2402 12.7401 17.4189 12.9485 17.6288 13.1218C17.7002 13.1609 17.7881 13.1525 17.8507 13.1005C17.8507 13.1005 18.3789 12.6489 18.5639 12.4903C18.6316 12.424 18.6331 12.3152 18.5668 12.2475C18.5657 12.2464 18.565 12.2456 18.5639 12.2445C18.3437 12.0127 18.2192 11.7061 18.2152 11.3864V9.94695C18.2152 9.33675 18.2573 8.7771 17.8057 8.36248C17.4142 8.04823 16.9237 7.88341 16.4219 7.89769C15.5374 7.89769 14.5521 8.22513 14.3437 9.31331C14.3269 9.40232 14.3855 9.48766 14.4741 9.5045C14.4774 9.50524 14.4804 9.5056 14.4837 9.50597L15.3737 9.6012C15.4528 9.6012 15.5293 9.52465 15.548 9.42173C15.6268 9.08073 15.944 8.84889 16.2926 8.87782C16.4967 8.8705 16.6922 8.9595 16.8208 9.11809C16.9794 9.32943 16.9343 9.91033 16.9343 9.91033C16.3769 9.96856 15.6718 10.0081 15.17 10.2275ZM16.7413 11.8358C16.6201 12.0823 16.374 12.2434 16.0996 12.2555C15.7432 12.2555 15.5345 11.9915 15.5345 11.5875C15.5345 10.7952 16.245 10.6553 16.9157 10.6553V10.856C16.9508 11.1923 16.8904 11.5318 16.7413 11.8358Z" fill="#4524FB" /> <path id="Vector_6" fill-rule="evenodd" clip-rule="evenodd" d="M6.38659 12.2449C6.16536 12.0134 6.0401 11.7069 6.03534 11.3868V9.94734C6.03534 9.33714 6.08039 8.77748 5.62878 8.36287C5.23248 8.04678 4.73582 7.88379 4.22927 7.9032C3.34474 7.9032 2.35692 8.23065 2.15108 9.31882C2.13423 9.40783 2.19283 9.49317 2.28147 9.51002C2.28476 9.51075 2.28769 9.51111 2.29099 9.51148L3.17845 9.60671C3.2605 9.60671 3.33705 9.53016 3.35536 9.42724C3.43411 9.08734 3.74946 8.85586 4.09742 8.88333C4.30143 8.87674 4.49665 8.96574 4.62558 9.1236C4.78417 9.33494 4.73912 9.91584 4.73912 9.91584C4.21096 9.97664 3.49528 10.0162 2.99093 10.2352C2.37816 10.4828 1.98333 11.085 2.00054 11.7457C2.00054 12.7068 2.60781 13.1877 3.39235 13.1877C3.98021 13.2196 4.54793 12.9694 4.92152 12.5141C5.0618 12.7474 5.24017 12.9555 5.44968 13.1295C5.52 13.1683 5.60717 13.1599 5.6687 13.1082C5.6687 13.1082 6.19686 12.6566 6.38439 12.498C6.45508 12.4306 6.45764 12.3185 6.39025 12.2479C6.38878 12.2471 6.38768 12.246 6.38659 12.2449ZM4.56441 11.8358C4.44281 12.0834 4.19558 12.2442 3.92015 12.2556C3.56377 12.2556 3.355 11.9915 3.355 11.5875C3.355 10.7952 4.06555 10.6553 4.73875 10.6553V10.856C4.77391 11.1923 4.71348 11.5318 4.56441 11.8358Z" fill="#4524FB" /> <path id="Vector_7" fill-rule="evenodd" clip-rule="evenodd" d="M7.28982 13.1137H8.21684C8.31244 13.1122 8.38972 13.035 8.39119 12.9394V10.4279C8.39119 9.87847 8.36481 9.10748 9.03289 9.10748C9.70096 9.10748 9.60609 9.89971 9.60609 10.4279V12.9419C9.60866 13.0335 9.68081 13.1082 9.77238 13.1137H10.6994C10.7957 13.1166 10.8759 13.0412 10.8789 12.9449C10.8789 12.9441 10.8789 12.943 10.8789 12.9423V10.4282C10.8591 10.1228 10.8888 9.81584 10.966 9.51989C11.0572 9.29171 11.2752 9.13934 11.5206 9.13165C11.7846 9.09393 12.0289 9.27706 12.067 9.54114C12.0985 9.83598 12.1073 10.1323 12.0934 10.4286V12.9427C12.096 13.0342 12.1681 13.1089 12.2597 13.1144H13.1867C13.283 13.1174 13.3633 13.0419 13.3662 12.9456C13.3662 12.9449 13.3662 12.9438 13.3662 12.943V9.95099C13.3662 9.44115 13.427 8.86281 13.131 8.46431C12.6604 7.86986 11.7967 7.76914 11.2019 8.24016C11.0093 8.39289 10.8609 8.59434 10.7727 8.82362C10.5086 8.22404 10.1467 7.94422 9.5658 7.94422C9.00578 7.92297 8.5029 8.28558 8.34577 8.82362H8.32746V8.21525C8.32599 8.12002 8.24834 8.04347 8.15311 8.04347H7.28946C7.19423 8.04347 7.11658 8.12002 7.11511 8.21525V12.9397C7.11694 13.0353 7.19423 13.1126 7.28982 13.1137Z" fill="#4524FB" /> <path id="Vector_8" fill-rule="evenodd" clip-rule="evenodd" d="M30.6821 7.94308C30.0404 7.94308 29.676 8.25221 29.4171 8.9016H29.3987V8.17786C29.3808 8.09655 29.3075 8.04014 29.2244 8.04307H28.3662C28.2714 8.04307 28.1945 8.11999 28.1945 8.21485V12.9393C28.1945 13.0346 28.271 13.1122 28.3662 13.1137H29.2958C29.3911 13.1122 29.4676 13.0346 29.4676 12.9393V10.3883C29.4519 10.0791 29.5031 9.77002 29.6181 9.4825C29.7134 9.27153 29.9155 9.12905 30.1463 9.11001C30.3602 9.11001 30.7272 9.13894 30.7272 10.0978V12.9631C30.7385 13.0463 30.8074 13.1093 30.8909 13.1137H31.8231C31.9117 13.1159 31.9879 13.051 32 12.9631V9.98685C32 9.52719 32 8.88842 31.7597 8.5108C31.5271 8.14343 31.1169 7.92733 30.6821 7.94308Z" fill="#4524FB" /> </g> <g id="music"> <path id="Vector_9" fill-rule="evenodd" clip-rule="evenodd" d="M9.25544 19.6233C8.39087 19.6489 7.55595 19.9708 6.87195 20.5422C6.60885 19.9294 6.10361 19.6233 5.35623 19.6233C4.54365 19.6533 3.75934 19.9506 3.10727 20.4748L3.03477 20.0633C3.02838 19.9885 2.99692 19.9191 2.94585 19.8679C2.8893 19.8315 2.82409 19.8143 2.75843 19.8182H2.24224C2.12733 19.799 2.01972 19.8841 2.00239 20.0082C1.9992 20.0313 1.9992 20.0545 2.00239 20.0776V26.1106C1.98643 26.2346 2.06714 26.3493 2.18205 26.3666C2.20212 26.3695 2.22218 26.3695 2.24224 26.3661H2.95223C3.06714 26.3848 3.1743 26.2996 3.19162 26.1756C3.19482 26.1539 3.19482 26.1323 3.19208 26.1106V21.2274C3.71465 20.8597 4.32386 20.6613 4.94766 20.6559C5.2208 20.6308 5.48893 20.7465 5.67087 20.968C5.84187 21.2505 5.92167 21.5862 5.89795 21.9229V26.1106C5.88199 26.2346 5.9627 26.3493 6.07761 26.3666C6.09768 26.3695 6.11774 26.3695 6.13781 26.3661H6.8446C6.96133 26.3848 7.06986 26.2976 7.08718 26.1716C7.08992 26.1515 7.09038 26.1308 7.0881 26.1106V21.4189C7.09175 21.3539 7.09175 21.2889 7.0881 21.2234C7.6166 20.8568 8.229 20.6554 8.8569 20.6417C9.12958 20.6156 9.39725 20.7317 9.57692 20.9537C9.75065 21.2348 9.83182 21.5714 9.80719 21.9086V26.0963C9.79123 26.2204 9.87194 26.3351 9.98685 26.3523C10.0069 26.3552 10.027 26.3552 10.047 26.3518H10.757C10.8719 26.3705 10.9791 26.2853 10.9964 26.1613C10.9996 26.1396 10.9996 26.118 10.9969 26.0963V21.5606C11.0247 21.0433 10.8656 20.5344 10.5532 20.1411C10.2103 19.7749 9.73697 19.5864 9.25544 19.6233Z" fill="#4524FB" /> <path id="Vector_10" fill-rule="evenodd" clip-rule="evenodd" d="M17.7129 19.6224H16.8931C16.7604 19.6032 16.6361 19.6884 16.6161 19.8126C16.6124 19.8358 16.6124 19.859 16.6161 19.8821V24.7186C16.0248 25.1084 15.323 25.3248 14.6001 25.3406C14.2526 25.3697 13.9093 25.2479 13.6703 25.0099C13.4507 24.7087 13.3475 24.3465 13.378 23.9828V19.8816C13.3986 19.7574 13.3075 19.6411 13.1748 19.6224C13.1501 19.619 13.1253 19.619 13.1006 19.6224H12.2808C12.1481 19.6032 12.0238 19.6884 12.0038 19.8126C12.0001 19.8358 12.0001 19.859 12.0038 19.8821V24.3953C11.9701 24.9246 12.1597 25.4451 12.5314 25.8453C12.9363 26.212 13.4881 26.4007 14.0499 26.3643C15.016 26.346 15.949 26.0326 16.7072 25.4722L16.802 25.9236C16.8088 25.999 16.8473 26.0695 16.9083 26.1193C16.9715 26.1573 17.0463 26.1745 17.121 26.1691H17.7208C17.8534 26.1878 17.9772 26.1025 17.9972 25.9783C18.0009 25.9567 18.0008 25.935 17.9977 25.9133V19.8713C18.0124 19.7466 17.9161 19.6342 17.7829 19.6204C17.7592 19.6175 17.736 19.6185 17.7129 19.6224Z" fill="#4524FB" /> <path id="Vector_11" fill-rule="evenodd" clip-rule="evenodd" d="M22.5038 22.7233L21.4385 22.3434C21.1265 22.2538 20.8341 22.1135 20.5749 21.929C20.4246 21.7949 20.3442 21.6071 20.3546 21.4146C20.3546 20.869 20.7957 20.5959 21.6702 20.5959C22.1767 20.5945 22.6806 20.6635 23.1653 20.7995C23.2664 20.8326 23.3721 20.8537 23.4794 20.8618C23.5992 20.8618 23.6588 20.7856 23.6588 20.6338V20.2884C23.6661 20.2017 23.6407 20.115 23.5878 20.0432C23.5261 19.9794 23.4452 19.9339 23.3561 19.9119C22.8003 19.7198 22.2114 19.6216 21.6179 19.6216C20.9704 19.5934 20.3318 19.7716 19.8087 20.126C19.3593 20.4355 19.1011 20.9279 19.1172 21.4452C19.1172 22.2739 19.6231 22.8612 20.6345 23.2066L21.7558 23.6142C22.0368 23.6947 22.2991 23.8221 22.5297 23.9907C22.6713 24.1196 22.7475 24.2978 22.7392 24.4812C22.7542 24.7504 22.6241 25.0091 22.3913 25.172C22.0881 25.3487 21.7325 25.4321 21.3748 25.41C20.7408 25.4105 20.1104 25.321 19.506 25.1442C19.3966 25.1059 19.282 25.0805 19.1659 25.068C19.0539 25.068 19.0016 25.1442 19.0016 25.296V25.6414C18.9938 25.7248 19.0151 25.8081 19.0612 25.8795C19.1224 25.9437 19.2011 25.9916 19.2893 26.0174C19.9456 26.2579 20.6469 26.3753 21.3525 26.3628C22.0378 26.404 22.7179 26.2287 23.2809 25.8656C23.7563 25.5226 24.0237 24.989 23.9983 24.4324C24.0129 24.0568 23.8802 23.6889 23.6246 23.3963C23.3156 23.0921 22.931 22.8607 22.5038 22.7233Z" fill="#4524FB" /> <path id="Vector_12" d="M25.2016 19.6187H25.7984C25.9099 19.6187 26 19.7384 26 19.8855V26.1019C26 26.2495 25.9095 26.3687 25.7984 26.3687H25.2016C25.0901 26.3687 25 26.249 25 26.1019V19.8855C24.9996 19.7379 25.0901 19.6187 25.2016 19.6187Z" fill="#4524FB" /> <path id="Vector_13" fill-rule="evenodd" clip-rule="evenodd" d="M31.836 25.1139C31.7682 25.1187 31.7015 25.1318 31.6367 25.1522C31.2506 25.2657 30.8495 25.3258 30.4459 25.3306C29.8666 25.3791 29.2943 25.1813 28.8786 24.7885C28.5457 24.4296 28.3791 23.8642 28.3791 23.0927V22.9283C28.3791 22.1384 28.5432 21.5623 28.8715 21.201C29.1974 20.8514 29.733 20.6627 30.4715 20.6627C30.839 20.6637 31.2045 20.7142 31.5574 20.8131C31.6267 20.8349 31.6985 20.848 31.7707 20.8514C31.8832 20.8514 31.9409 20.7675 31.9409 20.5963V20.2467C31.949 20.1579 31.9289 20.0687 31.8832 19.9916C31.8275 19.9325 31.7562 19.8888 31.6769 19.8655C31.2271 19.7065 30.7516 19.6245 30.2722 19.6245C29.3721 19.5707 28.4915 19.8927 27.8544 20.509C27.2862 21.0963 27 21.9323 27 23.0088C27 24.0853 27.2786 24.9247 27.8288 25.4984C28.4624 26.1051 29.3349 26.4193 30.225 26.3621C30.7416 26.3718 31.2552 26.2801 31.7346 26.0929C31.8174 26.0677 31.8907 26.0192 31.9444 25.9533C31.9861 25.8796 32.0047 25.7957 31.9987 25.7123V25.3622C32.0097 25.191 31.952 25.1139 31.836 25.1139Z" fill="#4524FB" /> <path id="Vector_14" fill-rule="evenodd" clip-rule="evenodd" d="M25.5931 17.3698C25.4334 17.3593 25.2766 17.4232 25.1597 17.5462C24.9468 17.8102 24.9468 18.213 25.1597 18.4774C25.4109 18.712 25.7752 18.712 26.0265 18.4774C26.2394 18.2134 26.2394 17.8106 26.0265 17.5462C25.9095 17.4232 25.7527 17.3593 25.5931 17.3698Z" fill="#4524FB" /> </g> </g> </svg> Amazon Music </a> <a class="flex items-center gap-2 py-2" href="https://feeds.buzzsprout.com/221709.rss"> <svg viewBox="0 0 34 34" fill="none" xmlns="http://www.w3.org/2000/svg" class=" inline w-7 h-7"> <g id="rss_feed"> <path id="rss-feed" d="M10.0769 27.9658C10.0768 30.1982 8.27107 32 6.03577 32C3.80909 32 2 30.1982 2 27.9658C2 25.7452 3.80909 23.9231 6.03577 23.9231C8.27117 23.9231 10.0769 25.7452 10.0769 27.9658ZM21.6154 32H15.8936C15.8936 28.2789 14.4464 24.7763 11.8232 22.1552C9.19734 19.5286 5.70936 18.0787 2 18.0787V12.3846C12.8127 12.3846 21.6154 21.1832 21.6154 32ZM32 32H26.2306C26.2306 18.6318 15.3572 7.75244 2 7.75244V2C18.5405 2 32 15.4627 32 32Z" fill="#F5A623" /> </g> </svg> RSS Feed </a> <a class="inline-block mt-3 font-bold" href="/221709/follow">See All</a> </div> </div> </aside> </div> </main> <footer class="mt-8 p-12 border-t border-gray-100 bg-gray-50"> <div class="grid justify-items-center mx-auto text-center"> <img alt="AHLA's Speaking of Health Law Artwork" class="w-[80px] h-[80px] rounded-md" src="https://www.buzzsprout.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElPcEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7729db373a8759c6d9056ad46fa486996bfd020c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdDam9MWm05eWJXRjBPZ2hxY0djNkUzSmxjMmw2WlY5MGIxOW1hV3hzV3docEFuZ0ZhUUo0QlhzR09nbGpjbTl3T2d0alpXNTBjbVU2RUdSbFptRjFiSFJmZFhKc1NTSTVhSFIwY0hNNkx5OTNkM2N1WW5WNmVuTndjbTkxZEM1amIyMHZhVzFoWjJWekwyRnlkSGR2Y210elgyeGhjbWRsTG1wd1p3WTZCa1ZVT2dwellYWmxjbnNHT2d4eGRXRnNhWFI1YVVFNkVHTnZiRzkxY25Od1lXTmxTU0lKYzNKbllnWTdDMVE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--2a89ede784d6e184500689d6dcbd55b204c8d4ad/AHLA_Buzzsprout.jpg" /> <div class="py-3">AHLA's Speaking of Health Law</div> <ul class=" flex flex-wrap gap-7 pt-5"> <li> <a target="_blank" href="https://www.facebook.com/ahlafb/"> <svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 310 310" xml:space="preserve" class="w-5 h-5 fill-gray"> <g id="XMLID_834_"> <path id="XMLID_835_" d="M81.703,165.106h33.981V305c0,2.762,2.238,5,5,5h57.616c2.762,0,5-2.238,5-5V165.765h39.064 c2.54,0,4.677-1.906,4.967-4.429l5.933-51.502c0.163-1.417-0.286-2.836-1.234-3.899c-0.949-1.064-2.307-1.673-3.732-1.673h-44.996 V71.978c0-9.732,5.24-14.667,15.576-14.667c1.473,0,29.42,0,29.42,0c2.762,0,5-2.239,5-5V5.037c0-2.762-2.238-5-5-5h-40.545 C187.467,0.023,186.832,0,185.896,0c-7.035,0-31.488,1.381-50.804,19.151c-21.402,19.692-18.427,43.27-17.716,47.358v37.752H81.703 c-2.762,0-5,2.238-5,5v50.844C76.703,162.867,78.941,165.106,81.703,165.106z"/> </g> </svg> </a> </li> <li> <a target="_blank" href="https://www.linkedin.com/company/1532976/"> <svg viewBox="0 0 19 18" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" class="w-5 h-5 fill-gray"> <g id="Linkedin" stroke="none" stroke-width="1" fill-rule="evenodd"> <g id="Linkedin" transform="translate(-272.000000, -45.000000)"> <g id="Linkedin" transform="translate(272.000000, 45.000000)"> <polygon id="Path" points="4.27540224 5.71779313 0.238700218 5.71779313 0.238700218 17.5787127 4.27540224 17.5787127"></polygon> <path d="M4.54126962,2.0487322 C4.51506984,0.885776552 3.66466504,1.42108547e-14 2.28373471,1.42108547e-14 C0.902804369,1.42108547e-14 1.13686838e-13,0.885776552 1.13686838e-13,2.0487322 C1.13686838e-13,3.18759902 0.876120893,4.0988814 2.23133513,4.0988814 L2.25713184,4.0988814 C3.66466504,4.0988814 4.54126962,3.18759902 4.54126962,2.0487322 Z" id="Path"></path> <path d="M18.833294,10.7780239 C18.833294,7.13486242 16.8418683,5.43927576 14.1855323,5.43927576 C12.0423091,5.43927576 11.0827519,6.59050188 10.5469864,7.39810778 L10.5469864,5.71810802 L6.50980073,5.71810802 C6.56300646,6.83107539 6.50980073,17.5790276 6.50980073,17.5790276 L10.5469864,17.5790276 L10.5469864,10.9549116 C10.5469864,10.6004278 10.5731862,10.2468099 10.6799201,9.99301113 C10.9716648,9.28483073 11.6359302,8.55161683 12.7511544,8.55161683 C14.2124576,8.55161683 14.796592,9.63923582 14.796592,11.233114 L14.796592,17.5787127 L18.8331328,17.5787127 L18.833294,10.7780239 Z" id="Path"></path> </g> </g> </g> </svg> </a> </li> <li> <a target="_blank" href="https://twitter.com/amerhealthlaw"> <svg viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg" class="w-5 h-5 fill-gray"> <path d="M13.6468 10.4686L20.9321 2H19.2057L12.8799 9.3532L7.82741 2H2L9.64031 13.1193L2 22H3.72649L10.4068 14.2348L15.7425 22H21.57L13.6464 10.4686H13.6468ZM11.2821 13.2173L10.508 12.1101L4.34857 3.29968H7.00037L11.9711 10.4099L12.7452 11.5172L19.2066 20.7594H16.5548L11.2821 13.2177V13.2173Z" fill=""/> </svg> </a> </li> <li> <a target="_blank" href="https://www.americanhealthlaw.org/education-events/speaking-of-health-law-podcasts"> <svg viewBox="0 0 18 18" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" class="w-5 h-5 fill-gray"> <g stroke="none" stroke-width="1" fill-rule="evenodd"> <g transform="translate(-233.000000, -45.000000)" fill-rule="nonzero"> <g transform="translate(233.000000, 45.000000)"> <path d="M2.1309505,0 L16.0465545,0 C16.5839881,0 17.0692218,0.219384 17.4312178,0.57375 C17.7827881,0.938664 17.9992871,1.429452 17.9992871,1.97226 L17.9992871,16.02774 C17.9992871,16.570548 17.7820752,17.060634 17.4312178,17.42625 C17.0699168,17.781336 16.5839881,18 16.0465545,18 L2.13023762,18 C1.59280396,18 1.1075703,17.780616 0.745574257,17.42625 C0.39400396,17.061336 0.17750495,16.570548 0.17750495,16.02774 L0.17750495,1.97226 C0.17750495,1.429452 0.394716832,0.939366 0.745574257,0.57375 C1.10687525,0.218664 1.59280396,1.43884904e-15 2.13023762,1.43884904e-15 L2.1309505,0 Z M10.344297,11.71836 L11.7080733,13.106322 C11.9252851,13.325706 11.9252851,13.680072 11.7080733,13.899438 C11.4908614,14.118804 11.140004,14.118822 10.9228099,13.899438 L9.55903366,12.511476 L8.39156436,13.69062 C8.17435248,13.910004 7.82349505,13.910004 7.60630099,13.69062 C7.52345822,13.6069488 7.47194079,13.5134316 7.45105723,13.408668 L6.32466713,9.140688 C6.24182436,8.848188 6.41795347,8.535294 6.71729881,8.462178 C6.8203301,8.4305376 6.91362356,8.4305376 7.00690277,8.462178 L11.2527642,9.609678 C11.5521166,9.682803 11.7282493,9.995688 11.6453958,10.298034 C11.6140687,10.3922532 11.5729949,10.4752206 11.5005939,10.548342 L10.3435681,11.716938 L10.344297,11.71836 Z M8.84616238,10.121562 L7.64736238,9.79812 L8.28784158,12.2085 L9.15595842,11.321856 L9.16640091,11.321856 L10.0345177,10.445058 L8.84616238,10.121562 Z M5.74677624,2.253582 C6.05657228,2.253582 6.30440198,2.50389 6.30440198,2.816784 C6.30440198,3.11913 6.05657228,3.37014 5.74677624,3.37014 C5.4369802,3.37014 5.1891505,3.119832 5.1891505,2.816784 C5.1891505,2.50389 5.4369802,2.253582 5.74677624,2.253582 Z M7.42034851,2.253582 L14.1049426,2.253582 C14.404295,2.253582 14.6625683,2.50389 14.6625683,2.816784 C14.6625683,3.11913 14.404295,3.37014 14.1049426,3.37014 L7.42034851,3.37014 C7.11055248,3.37014 6.86272277,3.119832 6.86272277,2.816784 C6.86272277,2.50389 7.11055248,2.253582 7.42034851,2.253582 Z M4.0732396,2.253582 C4.38303564,2.253582 4.63086535,2.50389 4.63086535,2.816784 C4.63086535,3.11913 4.38303564,3.37014 4.0732396,3.37014 C3.77388713,3.37014 3.51561386,3.119832 3.51561386,2.816784 C3.51561386,2.50389 3.77388713,2.253582 4.0732396,2.253582 Z M16.8840713,5.624442 L1.29411089,5.624442 L1.29411089,16.027902 C1.29411089,16.267662 1.38739723,16.476498 1.54194059,16.622748 C1.68674257,16.7795442 1.89351089,16.873056 2.13089703,16.873056 L16.0472139,16.873056 C16.2846,16.873056 16.4913683,16.7788368 16.6361703,16.622748 C16.7914141,16.476498 16.884,16.267662 16.884,16.027902 L16.8840713,5.624442 Z M2.23403168,1.127322 C1.97575842,1.127322 1.73837228,1.2313836 1.57268317,1.409274 C1.39724911,1.5759144 1.29352277,1.81638 1.29352277,2.077236 L1.29352277,4.498056 L16.8834832,4.498056 L16.8834832,2.077236 C16.8834832,1.81638 16.7804519,1.57662 16.6043228,1.409274 C16.4393323,1.2320856 16.2012475,1.127322 15.9429743,1.127322 L2.2333901,1.127322 L2.23403168,1.127322 Z"></path> </g> </g> </g> </svg> </a> </li> </ul> </div> <div class="pt-10 text-xs text-gray text-center">All content © 2024 AHLA's Speaking of Health Law</div> </footer> </body> </html>